General Information of Drug (ID: DM7HXWT)

Drug Name
Nilotinib
Synonyms
NIL; Nilotinibum; Tasigna (Novartis); Nilotinib (INN/USAN); Nilotinib, AMN107, Tasigna; Tasigna, AMN-107, Nilotinib; L-1-yl)-3-(trifluoromethyl)phenyl]benzamide; Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-(9CI); 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazo; 4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]benzamide; 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide; Nilotinib (BCR-ABL inhibitor 2nd gen)
Indication
Disease Entry ICD 11 Status REF
Chronic myelogenous leukaemia 2A20.0 Approved [1]
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01EA03: Nilotinib
L01EA: BCR-ABL tyrosine kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 529.5
Logarithm of the Partition Coefficient (xlogp) 4.9
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Absorption
The drug is orally available []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Elimination
4% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 15 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 21.58252 micromolar/kg/day [4]
Chemical Identifiers
Formula
C28H22F3N7O
IUPAC Name
4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
Canonical SMILES
CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
InChI
InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
InChIKey
HHZIURLSWUIHRB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
644241
ChEBI ID
CHEBI:52172
CAS Number
641571-10-0
UNII
F41401512X
DrugBank ID
DB04868
TTD ID
D00STL
VARIDT ID
DR00013
INTEDE ID
DR1155
ACDINA ID
D00468
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fusion protein Bcr-Abl (Bcr-Abl) TTS7G69 BCR_HUMAN-ABL1_HUMAN Modulator [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [6]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [7]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [7]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Post-Translational Modifications [11]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [12]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [13]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Drug Response [14]
Breakpoint cluster region protein (BCR) OTCN76C1 BCR_HUMAN Post-Translational Modifications [15]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Drug Response [16]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [11]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Gene/Protein Processing [11]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Protein Interaction/Cellular Processes [13]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Protein Interaction/Cellular Processes [17]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1; GDSC2 2.6312 4.5302 0.3378 1.2234
NOS-1 [Human HNSCC] GDSC1; GDSC2 1.529 4.2363 -0.2012 6.1966
CHSA0011 GDSC1; GDSC2 1.8417 3.6972 1.5905 15.6474
CHSA8926 GDSC1; GDSC2 1.9142 3.8659 0.2383 2.723
HuO9 GDSC1; GDSC2 2.014 4.8336 -0.1518 4.8154
EW-13 GDSC1; GDSC2 2.1231 5.6189 -0.4538 6.3908
ES1 GDSC1; GDSC2 2.3412 4.3717 0.2571 1.9518
ES8 GDSC1; GDSC2 2.4154 4.6995 0.1541 2.3797
Hs 888.T CTRP2 2.4646 3.2978 2.4646 23.8491
CAL-72 GDSC1; GDSC2 2.4768 4.4355 0.3009 1.562
CADO-ES1 GDSC1; GDSC2 2.7218 4.94 0.2124 1.6913
EW-24 GDSC1; GDSC2 2.7928 4.1216 0.5654 0.3053
ES7 GDSC1; GDSC2 2.8751 6.7108 -0.4853 5.1281
HuO-3N1 GDSC1; GDSC2 2.9237 6.1013 -0.182 3.4012
H-EMC-SS GDSC1; GDSC2 2.9673 5.9671 -0.099 2.9085
EW-12 GDSC2 3.0452 4.497 2.4904 6.1291
SK-PN-DW GDSC1; GDSC2 3.1667 5.9269 0.022 2.0667
EW-18 GDSC1; GDSC2 3.1753 5.1696 0.3305 0.7935
ES6 GDSC1; GDSC2 3.2392 5.0763 0.3922 0.5575
EW-11 GDSC1; GDSC2 3.2637 8.1679 -0.9191 6.8384
EW-3 GDSC1; GDSC2 3.2869 5.7565 0.1497 1.3856
CHSA0108 GDSC1; GDSC2 3.4355 5.2075 2.472 4.8849
ES5 GDSC1; GDSC2 3.5262 8.5546 0.8738 14.179
EW-22 GDSC1; GDSC2 3.5309 5.7424 0.2624 0.7856
SaOS-2 GDSC1; GDSC2; CTRP2; CCLE 3.6703 5.4627 3.5859 16.105
SK-ES-1 GDSC1; GDSC2; CTRP2; CCLE 3.7313 6.5068 3.3802 16.6606
ES4 GDSC1; GDSC2 3.7687 5.5822 0.4136 0.2844
NY GDSC1; GDSC2 3.7799 8.6328 -0.8242 5.472
EW-7 GDSC1; GDSC2 3.7833 9.9135 -1.406 8.4998
EW-1 GDSC1; GDSC2 3.7847 5.6371 0.4003 0.3055
U-CH2 GDSC2 4.1537 6.5324 2.3457 4.1391
EW-16 GDSC1; GDSC2 4.5433 6.8171 0.266 0.333
A-673 GDSC1; GDSC2; CTRP2 4.8939 7.7681 4.1034 10.69
TC-71 GDSC1; GDSC2; CCLE 5.1453 6.6734 2.5022 0.2599
Hs 822.T CTRP2 7.0347 8.0751 5.6878 0.3673
CAL-78 GDSC1; GDSC2; CTRP2; CCLE 7.3683 9.5361 5.2394 1.5261
SK-N-MC CTRP2 7.4279 8.4725 5.7021 0.1679
MG-63 GDSC1; GDSC2; CTRP2; CCLE 7.5673 9.1323 5.5099 0.5288
HOS GDSC1; GDSC2; CTRP2; CCLE 7.908 9.5355 5.5017 0.3833
SW1353 CTRP2; CCLE 8.4004 9.8706 5.5708 0.1299
G-292 clone A141B1 GDSC1; GDSC2; CTRP2 8.403 10.0472 5.5099 0.2088
U2OS GDSC1; GDSC2; CTRP2; CCLE 8.5874 10.6244 5.3724 0.3853
SJSA-1 GDSC1; GDSC2; CTRP2 8.7185 10.4729 5.477 0.1836
MHH-ES-1 GDSC1; GDSC2; CTRP2; CCLE 11.7902 21.2802 2.5144 6.5155
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 224 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JK1 CTRP2 -11.0873 -0.6103 -11.3428 85.1305
MEC1 CTRP2 7.5941 8.9815 5.5802 0.3467
JM1 GDSC1; GDSC2; CTRP2 7.7989 10.2592 5.1571 1.4139
ALL-SIL GDSC1; GDSC2; CTRP2; CCLE -9.6949 -1.1764 -9.8264 84.8535
MOLM-6 CTRP2 -9.1904 -5.7957 -9.1905 93.587
KYO-1 CTRP2 -9.0154 -6.8631 -9.0154 95.6397
EoL-1 GDSC1; GDSC2; CTRP2 -8.9301 -5.7639 -8.9302 93.2263
Ku812 GDSC1; GDSC2; CTRP2; CCLE -8.3987 -4.8129 -8.3992 90.413
BV-173 GDSC1; GDSC2; CTRP2 -8.3341 0.0431 -8.5057 80.7807
JURL-MK1 GDSC1; CTRP2 -8.0747 -5.7831 -8.0747 91.5998
LAMA-84 GDSC1; GDSC2; CTRP2 -7.701 -5.5888 -7.701 90.0518
EM-2 GDSC1; GDSC2; CTRP2; CCLE -7.39 -0.8193 -7.4562 80.4796
NCO2 CTRP2; CCLE -7.263 -5.0237 -7.263 87.4855
MEG-01 GDSC1; GDSC2; CCLE -6.6416 -4.8454 -6.6416 80.1942
CML-T1 GDSC1; GDSC2; CTRP2 -6.134 -1.9279 -6.1406 78.5389
KCL-22 GDSC1; GDSC2; CTRP2; CCLE -5.9498 -3.8985 -5.9498 79.6658
K-562 GDSC1; GDSC2; CTRP2 -4.3363 6.4888 -5.4088 62.0977
Kasumi-1 GDSC1; GDSC2; CTRP2 -4.0562 -1.3452 -4.0569 67.1414
BE-13 GDSC1; GDSC2 -2.476 11.3692 -7.3053 44.3392
MY-M12 GDSC1; GDSC2 -1.8331 51.5453 -25.2099 49.9939
NKM-1 GDSC1; GDSC2 0.2271 4.3057 -1.3342 17.0596
OCI-Ly7 GDSC1; GDSC2 0.2734 2.301 0.208 29.8533
CTV-1 GDSC1; GDSC2 0.8612 2.5195 0.1216 5.9786
KMS-34 CTRP2; CCLE 0.9623 2.5921 0.9607 33.8629
KMOE-2 GDSC1; GDSC2 1.2679 3.6326 -0.1002 6.2242
GA-10 GDSC1; GDSC2 1.3242 3.6882 -0.0844 5.9785
Ramos.2G6.4C10 GDSC1; GDSC2 1.3474 4.5754 -0.5071 8.5658
HAL-01 GDSC1; GDSC2 1.3492 4.3379 -0.3876 7.8141
SU-DHL-5 GDSC1; GDSC2 1.3769 3.783 -0.0912 5.8869
SUP-B8 GDSC1; GDSC2 1.3918 2.5588 1.3644 18.8338
KMM-1 CCLE 1.464 4.8679 0.6041 17.3707
Karpas-1106P GDSC1; GDSC2 1.5086 4.4552 -0.3242 7.0114
ME1 GDSC1; GDSC2 1.5118 3.0806 0.3491 2.8489
MOLT-4 GDSC1; GDSC2 1.5321 3.347 0.2349 3.4981
CCRF-CEM GDSC1; GDSC2 1.6192 5.1008 -0.56 8.1962
MHH-PREB-1 GDSC1; GDSC2 1.6263 3.2584 0.3404 2.6678
P32/ISH GDSC1; GDSC2 1.6314 3.6891 0.1383 3.8701
VAL GDSC1; GDSC2 1.6986 5.0358 -0.4694 7.445
U-698-M GDSC1; GDSC2 1.7096 3.5806 0.2423 3.0842
KOPN-8 GDSC1; GDSC2 1.7244 3.3029 0.3817 2.2422
KMS-18 CTRP2 1.7432 3.2932 1.7401 28.6656
IM-9 GDSC1; GDSC2 1.7562 3.0596 0.5112 1.4674
RPMI-8866 GDSC1 1.7966 5.2667 -0.5114 9.251
HuT 78 CCLE 1.8212 3.6377 1.4968 11.6524
DB GDSC1; GDSC2; CTRP2 1.8437 4.7736 1.7341 28.3556
WSU-NHL GDSC1; GDSC2 1.8468 4.3385 -0.0272 4.4134
KMS-28BM CTRP2 1.8855 4.6296 1.7992 27.9981
Karpas-45 GDSC1; GDSC2 1.955 3.8341 0.2776 2.4303
ML-2 GDSC1; GDSC2 1.9834 4.4322 0.0179 3.8721
SUP-B15 GDSC1; GDSC2; CTRP2 2.0126 30.175 -9.5261 43.4493
KY821 GDSC1; GDSC2 2.0188 4.6781 -0.0751 4.3506
CTB-1 GDSC1; GDSC2 2.0569 6.7854 0.4489 21.1595
Daudi GDSC1; GDSC2; CTRP2 2.061 3.2408 2.0604 26.5398
BALL-1 GDSC1; GDSC2 2.0654 4.4493 0.0617 3.4634
WIL2 NS GDSC1; GDSC2 2.0775 4.2423 0.1645 2.8566
OCI-AML-3 GDSC1; GDSC2; CTRP2 2.1002 6.266 1.6775 27.7261
GR-ST GDSC1; GDSC2 2.1808 6.5264 -0.8517 8.6327
ARH-77 GDSC1; GDSC2 2.2185 4.4846 0.1379 2.7692
HD-MY-Z CTRP2 2.2258 3.4812 2.2243 25.445
KMS-11 GDSC1; GDSC2; CTRP2; CCLE 2.2372 5.2752 2.0714 25.9299
SCC-3 GDSC2 2.2399 7.3598 -1.2151 10.6148
MN-60 GDSC1; GDSC2 2.2767 4.2676 0.2675 1.9879
MEC-1 CCLE 2.2808 5.6667 1.0284 12.6076
Karpas-231 GDSC1; GDSC2 2.2904 3.8958 0.4336 1.1574
ALL-PO GDSC1; GDSC2 2.2989 6.4581 -0.7371 7.697
LC4-1 GDSC1; GDSC2 2.3267 8.8487 -1.8811 14.0714
YT GDSC1; GDSC2 2.3481 7.4729 -1.1934 10.2412
Farage GDSC1; GDSC2 2.3749 5.8856 1.1852 15.9432
Loucy GDSC1; GDSC2 2.382 4.0573 0.4117 1.157
H9 GDSC1; GDSC2 2.3937 6.6576 -0.7686 7.6792
TK [Human B-cell lymphoma] GDSC1; GDSC2 2.4487 4.0386 0.4512 0.9198
RC-K8 GDSC1; GDSC2 2.4569 4.314 0.3419 1.3922
PL-21 GDSC1; GDSC2 2.5116 4.857 1.8063 11.8199
QIMR-WIL GDSC1; GDSC2 2.5345 5.0438 1.7408 12.1259
697 GDSC1; GDSC2; CTRP2; CCLE 2.54 4.3943 2.5139 23.4343
ATN-1 GDSC1; GDSC2 2.588 4.3423 0.3937 1.0276
Jiyoye GDSC1; GDSC2 2.6319 4.5281 0.339 1.2174
THP-1 GDSC1; GDSC2; CTRP2 2.6445 3.8684 2.642 22.6588
NK-92MI GDSC2 2.646 3.4848 2.5342 7.3848
SIG-M5 GDSC2; CTRP2; CCLE 2.6571 3.9882 2.6526 22.5814
TALL-1 [Human adult T-ALL] GDSC2; CTRP2 2.693 5.8048 2.4494 23.1712
BC-3 GDSC2 2.7161 3.5522 2.5861 6.7872
JM-1 CCLE 2.7386 4.8398 1.8541 6.892
AML-193 CTRP2 2.7483 4.0213 2.7444 21.9722
TUR GDSC1; GDSC2 2.7705 4.6859 0.3404 1.0785
CRO-AP2 GDSC1; GDSC2 2.8057 5.9296 1.5663 12.2602
Hs 445 GDSC2 2.821 4.8324 0.3049 1.1778
VL51 GDSC1; GDSC2 2.8389 5.0567 0.2219 1.5184
CESS GDSC1; GDSC2 2.8794 4.5754 0.4319 0.6504
JSC-1 GDSC1; GDSC2 2.9126 5.5576 0.0486 2.2437
L-428 GDSC1; GDSC2; CTRP2; CCLE 2.9157 4.3222 2.9061 20.8759
MOLT-3 CTRP2 2.9612 6.463 2.5566 21.9679
KMS-21-BM CTRP2 3.0333 17.324 -2.2665 34.8574
HH [Human lymphoma] GDSC1; GDSC2; CTRP2; CCLE 3.0463 6.2439 2.7159 21.1342
BC-1 GDSC1; GDSC2 3.0514 5.062 0.3184 0.9273
SU-DHL-16 GDSC1; GDSC2 3.0775 5.2724 2.1362 7.9641
MHH-CALL-2 GDSC1; GDSC2 3.1019 4.6351 0.4994 0.3361
DoHH2 GDSC1; GDSC2; CCLE 3.1193 4.1205 2.7433 3.5798
DG-75 GDSC1; GDSC2 3.1468 5.2075 0.3035 0.9087
MLMA GDSC1; GDSC2 3.1477 10.472 -2.0876 13.2447
Mono-Mac-1 CTRP2; CCLE 3.2967 7.5388 2.5373 21.06
SUP-M2 GDSC1; GDSC2; CCLE 3.2988 4.8432 2.314 2.9552
HC-1 GDSC1; GDSC2 3.341 4.9332 0.4836 0.2819
Sc-1 GDSC1 3.3446 4.6131 0.5949 0.1233
P30/OHK GDSC1; GDSC2 3.384 4.8979 0.5116 0.214
OPM-2 GDSC1; GDSC2; CTRP2; CCLE 3.4302 5.8784 3.2351 18.0944
EB1 CTRP2; CCLE 3.667 5.4545 3.5838 16.1227
RS4;11 GDSC1; GDSC2; CTRP2 3.7431 10.5893 1.6534 23.0901
L-1236 GDSC1; GDSC2 3.7446 6.1173 0.2098 0.8213
KG-1 GDSC1; GDSC2; CCLE 3.7535 6.8822 1.6454 5.5106
SUP-T11 CTRP2 3.8242 5.7547 3.694 15.2411
DEL GDSC1; GDSC2; CTRP2; CCLE 3.9006 4.8862 3.8931 14.3074
BDCM CCLE 3.9269 5.8106 2.2714 2.1506
CA46 GDSC1; GDSC2; CTRP2 4.016 6.088 3.8187 14.205
BL-41 GDSC1; GDSC2; CCLE 4.0368 5.8844 2.3028 1.7972
Karpas-620 GDSC1; GDSC2; CTRP2; CCLE 4.1938 7.2756 3.5931 14.5417
KE-37 GDSC1; GDSC2; CTRP2 4.2175 7.6078 3.4806 14.9141
ROS-50 GDSC1; GDSC2 4.2201 7.5081 1.9219 6.3336
BONNA-12 GDSC2 4.3817 7.0153 2.2661 4.1576
U-937 CTRP2; CCLE 4.3883 7.7905 3.5791 14.0751
KMS-12-BM GDSC1; GDSC2; CTRP2; CCLE 4.405 8.088 3.465 14.4825
MOLP-2 CTRP2 4.4086 7.5137 3.7194 13.4704
HPB-ALL CTRP2 4.5428 8.9152 3.2236 15.0986
CMK-86 CCLE 4.5824 7.9505 1.6863 4.0086
Pfeiffer CTRP2; CCLE 5.1282 8.6009 3.9405 10.7853
MJ CCLE 5.1301 10.4382 0.8709 7.1191
Namalwa GDSC1; GDSC2; CTRP2 5.4742 9.0648 4.0361 9.609
A4/Fukuda GDSC1; GDSC2; CTRP2 5.7507 12.4809 1.8971 12.6
EB2 GDSC1; GDSC2; CCLE 5.9173 7.6966 2.4277 0.182
HEL 92.1.7 CTRP2; CCLE 5.9587 7.0191 4.6749 0.4827
SET-2 CTRP2 5.9699 8.2994 4.8542 5.1483
Hs 611.T CTRP2 6.4251 10.5251 4.1129 7.4101
KO52 CTRP2; CCLE 6.7455 12.2927 3.4836 9.4513
REC-1 CTRP2 6.8037 13.4422 2.9577 11.4726
Toledo CTRP2; CCLE 6.9308 9.3475 5.0603 2.7058
MC116 GDSC1; GDSC2; CTRP2; CCLE 6.9868 12.8695 3.3819 9.4531
SU-DHL-10 GDSC2; CTRP2; CCLE 6.99 8.1532 5.6348 0.5465
SU-DHL-1 GDSC2; CTRP2 7.065 8.2432 5.6342 0.4964
Ci-1 CTRP2; CCLE 7.0905 8.5246 5.5294 0.7976
KMS-26 CTRP2; CCLE 7.0961 14.8467 2.486 12.7999
LP-1 GDSC1; GDSC2; CTRP2; CCLE 7.1357 9.7745 4.9915 2.7095
A3/Kawakami GDSC1; GDSC2; CTRP2 7.167 8.2248 5.6879 0.2973
WSU-DLCL2 GDSC1; GDSC2; CTRP2 7.2875 8.8512 5.4916 0.7619
P12-Ichikawa GDSC1; GDSC2; CTRP2; CCLE 7.3385 13.5727 3.2967 9.2185
Karpas-299 GDSC1; GDSC2; CTRP2; CCLE 7.3729 9.2811 5.3531 1.1343
OCI-AML-2 GDSC1; GDSC2; CTRP2; CCLE 7.3739 8.4709 5.6812 0.2243
Karpas-422 GDSC1; GDSC2; CTRP2; CCLE 7.4057 8.6772 5.6164 0.3503
NOMO-1 GDSC1; GDSC2; CTRP2 7.4497 8.9546 5.527 0.5516
RL GDSC1; GDSC2; CTRP2 7.4545 10.1724 5.0035 2.2867
HEL GDSC1; GDSC2; CTRP2 7.4662 8.918 5.5491 0.4842
OCI-AML-5 GDSC1; CTRP2; CCLE 7.4819 8.395 5.7499 0.0857
TF-1 CTRP2 7.4823 8.6912 5.6432 0.2592
Mino CTRP2; CCLE 7.4905 8.6077 5.6774 0.1916
MOLM-13 GDSC1; GDSC2; CTRP2 7.5003 16.4706 1.9893 13.9556
SKM-1 GDSC1; GDSC2; CTRP2 7.5185 9.184 5.4667 0.675
MOTN-1 CTRP2 7.521 10.5908 4.8521 2.7763
HuNS1 CTRP2 7.5438 11.5656 4.4111 4.4518
KMS-27 CTRP2 7.5496 14.6091 2.9425 10.2799
EJM GDSC1; GDSC2; CTRP2 7.5556 11.0225 4.6737 3.4141
OCI-M1 GDSC1; GDSC2; CTRP2 7.5582 8.8426 5.6177 0.2818
Mono-Mac-6 GDSC1; GDSC2; CTRP2 7.5703 15.895 2.3258 12.602
Granta-519 GDSC1; GDSC2; CTRP2; CCLE 7.6191 9.4679 5.3988 0.8024
SEM CTRP2 7.6212 8.8859 5.6271 0.2401
BL-70 CTRP2; CCLE 7.6611 8.5845 5.7486 0.0591
NU-DUL-1 GDSC1; GDSC2; CTRP2 7.6907 9.6333 5.3655 0.8504
P31/FUJ GDSC1; GDSC2; CTRP2; CCLE 7.7306 9.1139 5.5868 0.2786
HL-60 GDSC1; GDSC2; CTRP2 7.742 9.0313 5.6216 0.2108
KE-97 CTRP2; CCLE 7.7698 9.8872 5.2992 0.9908
KMS-20 CTRP2 7.7721 16.5037 2.1755 12.8269
NB4 GDSC1; GDSC2; CTRP2 7.7769 8.7282 5.7404 0.0523
SU-DHL-4 GDSC1; GDSC2; CTRP2; CCLE 7.7785 12.8024 3.9784 5.842
OCI-Ly3 CTRP2 7.7961 9.07 5.6286 0.1838
MV4-11 GDSC1; GDSC2; CTRP2 7.8059 20.7189 0.1185 19.5156
SU-DHL-6 GDSC1; GDSC2; CTRP2; CCLE 7.8064 11.213 4.739 2.8749
CMK GDSC1; CTRP2 7.8242 8.9702 5.6743 0.1127
NALM-6 GDSC1; GDSC2; CTRP2 7.8304 9.5975 5.4444 0.552
HT GDSC1; GDSC2; CTRP2; CCLE 7.8397 9.1662 5.6107 0.2005
L-540 GDSC1; GDSC2; CTRP2 7.8654 9.8499 5.3601 0.7522
MM1.S GDSC1; GDSC2; CTRP2 7.9859 9.4441 5.5668 0.231
Jurkat GDSC1; GDSC2; CTRP2; CCLE 7.9944 9.3693 5.5969 0.1808
GDM-1 GDSC1; GDSC2; CTRP2 8.0013 10.176 5.2921 0.855
Raji GDSC1; GDSC2; CTRP2; CCLE 8.0148 9.3416 5.6144 0.1511
MOLP-8 GDSC1; GDSC2; CTRP2; CCLE 8.0484 9.6706 5.5086 0.3155
MOLT-16 GDSC1; GDSC2; CTRP2; CCLE 8.0599 9.3774 5.6184 0.1363
ME1 CTRP2 8.0687 9.5946 5.5444 0.2443
SUP-HD1 GDSC1; GDSC2; CTRP2 8.0861 10.2431 5.3045 0.77
PL21 CTRP2 8.087 9.5556 5.5656 0.2048
KHM-1B CTRP2; CCLE 8.0998 9.8286 5.4707 0.3711
RPMI-6666 GDSC1; GDSC2; CTRP2 8.1022 9.6828 5.5255 0.2667
OCI-Ly19 GDSC1; GDSC2; CTRP2 8.1296 9.7688 5.5048 0.2948
SUP-T1 GDSC1; GDSC2; CTRP2; CCLE 8.1306 9.7725 5.5039 0.2963
NCI-H929 GDSC1; GDSC2; CTRP2 8.1337 9.6705 5.5422 0.2293
SK-MM-2 GDSC1; GDSC2; CTRP2; CCLE 8.1505 10.1238 5.3799 0.5475
OCI-Ly10 CTRP2 8.2019 11.4963 4.8371 2.1259
MOLM-16 GDSC1; GDSC2; CTRP2 8.2315 9.7011 5.5682 0.1662
M-07e CTRP2 8.2371 9.9695 5.4738 0.3158
Ri-1 CTRP2 8.2578 19.0146 1.2987 15.1074
U266B1 GDSC1; GDSC2; CTRP2 8.2839 9.8697 5.5281 0.2113
Reh GDSC1; GDSC2; CTRP2; CCLE 8.2875 9.8499 5.5365 0.1979
RPMI-8402 GDSC1; GDSC2; CTRP2; CCLE 8.3064 9.6351 5.6181 0.0945
ST486 GDSC1; GDSC2; CTRP2 8.3068 9.7398 5.5823 0.1333
RPMI-8226 GDSC1; GDSC2; CTRP2 8.3235 9.7217 5.5945 0.1164
P3HR-1 CTRP2; CCLE 8.3375 16.6078 2.5301 10.6374
SR GDSC1; GDSC2; CTRP2 8.3388 9.9825 5.5087 0.2268
SU-DHL-8 GDSC2; CTRP2; CCLE 8.3422 17.122 2.2841 11.5359
DND-41 GDSC1; GDSC2; CTRP2 8.3881 10.1541 5.4658 0.2824
MOLT-13 GDSC1; GDSC2; CTRP2 8.3911 9.8281 5.5821 0.1188
AMO1 GDSC1; GDSC2; CTRP2; CCLE 8.4156 18.4954 1.6674 13.6116
KM-H2 GDSC1; GDSC2; CTRP2 8.418 10.5268 5.3395 0.5176
JJN-3 GDSC1; GDSC2; CTRP2 8.4856 14.7454 3.5213 6.6741
Ki-JK CTRP2 8.5347 10.1224 5.5321 0.151
F-36P CTRP2; CCLE 8.5437 13.5997 4.0905 4.4508
PF-382 GDSC1; GDSC2; CTRP2 8.7049 10.306 5.5299 0.1244
MHH-CALL-4 GDSC2; CTRP2 8.7171 10.3465 5.5203 0.1327
EHEB GDSC1; CTRP2 8.7272 10.2528 5.5558 0.0961
HDLM-2 GDSC1; GDSC2; CTRP2 8.7614 10.7619 5.3906 0.2993
JVM-3 GDSC1; GDSC2; CTRP2; CCLE 8.7699 16.5807 2.8379 8.8753
Kasumi-2 CTRP2; CCLE 8.8954 15.4568 3.4488 6.4285
JVM-2 GDSC1; GDSC2; CTRP2 9.039 11.2905 5.3069 0.3578
MHH-CALL-3 CTRP2 9.1724 11.1269 5.4147 0.1734
RCH-ACV GDSC1; GDSC2; CTRP2 9.4606 20.5008 1.427 12.8768
JeKo-1 GDSC1; GDSC2; CTRP2 10.2465 19.4444 2.4384 8.426
Peer CTRP2 10.8257 35.0019 -4.6686 25.3732
L-363 GDSC1; GDSC2; CTRP2; CCLE 12.0421 25.6153 0.6912 11.8678
⏷ Show the Full List of 224 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 7.4148 10.6433 4.762 3.248
TE8 CTRP2 8.7773 10.56 5.4682 0.183
T.T GDSC1; GDSC2 1.574 3.8826 0.0046 4.8159
TE-8 GDSC1; GDSC2 2.9254 5.3021 0.1627 1.6913
KYSE-410 GDSC1; GDSC2; CTRP2; CCLE 3.1525 4.737 3.1268 19.3524
TE-5 GDSC1; GDSC2; CTRP2 3.2974 5.4698 3.1815 18.6982
TE-4 GDSC1; GDSC2 3.2995 5.082 0.4142 0.4647
TE-6 GDSC1; GDSC2; CTRP2 3.4345 4.7732 3.3534 11.7902
OE21 GDSC1; GDSC2; CTRP2; CCLE 3.5958 5.6385 3.471 16.7426
KYSE-270 GDSC1; GDSC2 4.2255 6.126 0.3901 0.206
TE-15 GDSC1 4.6366 6.5466 0.3908 0.1644
TE-11 GDSC1; GDSC2; CTRP2 7.6882 9.0753 4.602 0.0679
OE19 GDSC1; GDSC2; CTRP2 7.9634 9.8204 5.416 0.5533
KYSE-450 GDSC1; GDSC2; CTRP2 7.9816 10.112 5.3087 0.8215
EC-GI-10 GDSC1; GDSC2; CTRP2 8.0174 9.6256 5.5128 0.3185
KYSE-30 CTRP2; CCLE 8.1066 9.2217 5.6883 0.0576
KYSE-150 GDSC1; GDSC2; CTRP2 8.1147 9.2849 5.6698 0.072
COLO 680N GDSC1; GDSC2; CTRP2 8.1213 9.4945 5.6 0.1474
TE-9 GDSC1; GDSC2; CTRP2; CCLE 8.3103 9.8082 5.5597 0.1607
TE-1 GDSC1; GDSC2; CTRP2 8.3468 10.0205 5.4981 0.2412
OE33 GDSC1; GDSC2; CTRP2; CCLE 8.3536 10.0282 5.4979 0.2396
TE-14 CTRP2 8.4446 9.9539 5.5579 0.1369
KYSE-70 GDSC1; GDSC2; CTRP2 8.4637 9.9536 5.5649 0.1257
KYSE-510 GDSC1; GDSC2; CTRP2 8.5738 9.9668 5.5991 0.0775
TE-10 GDSC1; GDSC2; CTRP2 8.5742 10.4698 5.4237 0.2983
KYSE-520 GDSC1; GDSC2; CTRP2; CCLE 8.6991 10.6696 5.3998 0.3018
KYSE-140 GDSC1; GDSC2; CTRP2 8.9735 16.502 3.0087 7.969
KYSE-180 GDSC1; GDSC2; CTRP2 11.3307 21.6528 2.0817 8.3838
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 43 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 8.0796 9.432 5.6066 0.1476
PaTu 8988s CTRP2 2.1961 3.0967 2.196 25.6381
Panc 10.05 GDSC1; GDSC2; CTRP2; CCLE 3.4654 4.7953 3.4485 17.2384
PL45 CCLE 3.6649 5.6415 2.1838 3.0162
MIA PaCa-2 GDSC1; GDSC2; CTRP2; CCLE 3.6809 5.5355 3.584 16.0781
KP-1N GDSC1; GDSC2; CCLE 3.7819 7.285 1.469 6.3611
PL4 GDSC1; GDSC2 3.8164 5.7805 0.3615 0.3761
PK-1 CCLE 3.9249 6.132 2.1213 2.8916
KP-1NL CCLE 4.0101 6.7099 1.9042 3.8441
SU.86.86 GDSC1; GDSC2; CTRP2 4.1264 5.4773 4.0743 12.955
Capan-1 GDSC1; GDSC2; CTRP2 4.2317 5.9919 4.0802 12.6049
MZ-PC-1 GDSC1; GDSC2 4.241 6.7643 2.2933 4.127
AsPC-1 GDSC1; GDSC2; CTRP2; CCLE 4.2815 7.9102 3.4171 14.9931
SNU-410 CTRP2 4.8102 10.9281 2.5107 17.2893
PSN1 GDSC1; GDSC2; CTRP2 4.8932 7.0322 4.4278 9.4032
KP-4 GDSC1; GDSC2; CTRP2; CCLE 5.0073 6.3864 4.8037 7.6423
KP-2 GDSC1; GDSC2; CTRP2; CCLE 6.0488 6.7529 5.6938 1.4653
PaTu 8902 GDSC1; GDSC2; CTRP2 6.964 9.5962 4.964 3.0429
DAN-G GDSC1; GDSC2; CTRP2 7.7389 13.9197 3.4139 8.1337
PaTu 8988t GDSC1; GDSC2; CTRP2 7.7428 8.9685 5.6446 0.1729
Panc 03.27 GDSC1; GDSC2; CTRP2; CCLE 7.7892 11.4494 4.6205 3.337
YAPC GDSC1; GDSC2; CTRP2 7.8823 9.0875 5.6546 0.126
SW1990 GDSC1; GDSC2; CTRP2; CCLE 7.9456 13.5385 3.7388 6.5555
HPAF-II GDSC1; GDSC2; CTRP2 7.9979 10.1734 5.2916 0.8586
HPAC GDSC1; GDSC2; CTRP2; CCLE 8.0388 9.5752 5.5398 0.2614
Panc 05.04 CTRP2 8.0407 14.9905 3.1059 8.8916
SNU-213 CTRP2 8.0616 9.4294 5.6008 0.1593
QGP-1 GDSC1; GDSC2; CTRP2 8.0844 9.961 5.4141 0.4995
Panc 04.03 GDSC1; GDSC2; CTRP2; CCLE 8.2388 13.7868 3.8136 5.8725
BxPC-3 GDSC1; GDSC2; CTRP2 8.2461 11.1335 5.0159 1.5026
SUIT-2 GDSC1; GDSC2; CTRP2; CCLE 8.2603 9.6643 5.5916 0.1308
Panc 02.03 GDSC1; GDSC2; CTRP2; CCLE 8.2731 9.7297 5.5735 0.1505
HuP-T3 GDSC1; GDSC2; CTRP2; CCLE 8.3558 10.6036 5.2832 0.6768
Hs 766T GDSC1; GDSC2; CTRP2; CCLE 8.3887 9.8625 5.5693 0.1336
TCC-Pan2 CTRP2 8.4331 9.7898 5.61 0.085
Panc 08.13 GDSC1; GDSC2; CTRP2 8.4556 10.4752 5.3746 0.4289
KP-3 GDSC1; GDSC2; CTRP2; CCLE 8.5973 10.728 5.338 0.4486
CFPAC-1 GDSC1; GDSC2; CTRP2 8.6299 10.28 5.5119 0.1575
HuP-T4 GDSC1; GDSC2; CTRP2; CCLE 8.7982 13.8005 4.1498 3.9537
PK-59 CTRP2; CCLE 8.847 10.6255 5.4708 0.1665
Capan-2 GDSC1; GDSC2; CTRP2; CCLE 8.9111 10.4999 5.5363 0.0906
PK-45H CTRP2; CCLE 8.9683 10.9257 5.4103 0.2187
L3.3 CTRP2; CCLE 14.8725 26.6006 1.857 5.8183
⏷ Show the Full List of 43 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 78 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 10.6156 28.2323 -1.5093 19.4848
HMV-II GDSC1; GDSC2 1.2407 3.1853 0.1009 5.0301
WM278 GDSC1; GDSC2 1.438 4.8847 -0.5904 8.8454
G-mel GDSC1; GDSC2 1.6695 4.103 1.2581 18.1815
M14 GDSC1; GDSC2 1.7356 3.3079 0.3863 2.196
WM35 GDSC1; GDSC2 1.8492 4.9783 -0.3335 6.2635
CP50-MEL-B GDSC1; GDSC2 1.9781 3.4875 1.807 13.8998
Malme-3M CCLE 2.1657 4.2395 1.5973 9.9679
COLO 783 GDSC1; GDSC2 2.2598 3.1418 2.2066 10.556
Hs 938.T GDSC1; GDSC2; CCLE 2.288 4.4196 1.7796 11.04
MZ-MEL-7 GDSC1; GDSC2 2.4636 4.1537 2.0759 10.4276
SH-4 GDSC1; GDSC2 2.4695 5.0541 0.0271 2.9751
GAK GDSC1; GDSC2 2.489 3.8894 0.5281 0.5904
LB2518-MEL GDSC1; GDSC2 2.5408 3.8362 2.2895 8.914
A-431 GDSC1; GDSC2 2.563 3.6583 2.3825 8.3057
WM88 CTRP2; CCLE 2.637 3.8355 2.6349 22.7074
A-388 GDSC1; GDSC2 2.6586 5.2013 1.785 11.4359
Hs 934.T CTRP2 2.6846 3.1964 2.6846 22.3835
WM115 GDSC1; GDSC2; CTRP2 2.8119 5.1738 2.7105 21.8809
DJM-1 GDSC1; GDSC2 2.8209 5.5142 1.7846 10.9004
COLO 679 GDSC1; GDSC2; CCLE 2.8293 5.6129 1.5487 8.0757
451Lu GDSC1; GDSC2 2.8375 4.0895 2.4855 6.6579
Hs 688(A).T CTRP2 2.8849 3.4941 2.8849 21.0492
SK-MEL-24 GDSC1; GDSC2; CTRP2; CCLE 2.9771 4.9486 2.9201 20.6277
Hs 940.T GDSC1; GDSC2 2.9788 3.9108 2.7087 4.8377
WM983B CTRP2; CCLE 2.9894 5.5878 2.823 20.9263
SF8657 CCLE 2.999 5.5613 1.7186 6.9455
CP66-MEL GDSC1; GDSC2 3.0128 3.8045 2.7915 4.2292
MZ-MEL-2 GDSC1; GDSC2 3.0252 6.4908 1.4839 12.0702
UACC-62 GDSC1; GDSC2; CTRP2 3.1465 5.2182 3.063 19.5906
IGR-37 GDSC1; GDSC2; CTRP2; CCLE 3.1881 4.1494 3.1868 19.0332
WM266-4 CTRP2 3.3168 5.0623 3.2671 18.3395
Hs 895.T CTRP2; CCLE 3.3353 4.9223 3.3022 18.16
UACC-257 GDSC1; GDSC2; CTRP2 3.4541 5.3696 3.369 17.5472
CHL-1 GDSC1; GDSC2; CCLE 3.4601 5.2798 2.2171 3.1388
IST-MEL1 GDSC1; GDSC2 3.4784 5.2809 0.4116 0.3917
RPMI-7951 GDSC1; GDSC2; CTRP2 3.5752 4.1556 3.5752 16.4501
HT-144 GDSC1; GDSC2; CTRP2; CCLE 3.612 6.7617 3.1643 17.8107
MMAc-SF GDSC1; GDSC2 3.695 6.2139 2.1739 6.0367
MeWo GDSC1; GDSC2; CTRP2; CCLE 3.7735 5.2432 3.7301 15.2757
RVH-421 GDSC1; GDSC2; CTRP2; CCLE 3.8381 4.6891 3.8355 14.7075
WM1552C GDSC1; GDSC2 3.8584 5.411 0.5041 0.1231
VMRC-MELG GDSC1; GDSC2 3.8622 5.7227 2.5365 3.4795
WT2-iPS GDSC1; GDSC2; CTRP2; CCLE 4.2069 6.3814 3.9379 13.1984
LB373-MEL-D GDSC1; GDSC2 4.7506 6.1603 2.8435 0.6368
Hs 695T CCLE 4.8895 8.0975 1.8005 3.0365
SK-MEL-2 GDSC1; GDSC2; CTRP2; CCLE 7.0278 8.0019 5.7136 0.305
HMCB CTRP2; CCLE 7.0723 7.9997 5.7338 0.236
SK-MEL-28 GDSC1; GDSC2; CTRP2 7.2664 13.651 3.2052 9.7004
A101D GDSC1; GDSC2; CTRP2 7.3804 10.2539 4.9215 2.679
A2058 GDSC1; GDSC2; CTRP2; CCLE 7.5848 8.8108 5.6403 0.228
IGR-1 GDSC1; GDSC2; CTRP2 7.5929 9.3135 5.4492 0.6764
K029AX CTRP2; CCLE 7.6681 9.0357 5.5905 0.2946
Hs 936.T CTRP2; CCLE 7.6736 15.8883 2.4054 12.1351
IPC-298 GDSC1; GDSC2; CTRP2; CCLE 7.6948 11.9024 4.3501 4.493
IGR-39 CTRP2; CCLE 7.7452 9.4062 5.4816 0.5047
CJM [Human melanoma] CTRP2 7.746 8.8771 5.6782 0.1235
MDA-MB-435S CTRP2; CCLE 7.8444 9.3291 5.5529 0.3033
SK-MEL-31 GDSC1; GDSC2; CTRP2; CCLE 7.8944 10.3703 5.1592 1.3287
SK-MEL-30 GDSC1; GDSC2; CTRP2; CCLE 7.904 9.2928 5.5898 0.2165
WM1799 CTRP2; CCLE 7.9212 15.4482 2.8 10.2487
G-361 GDSC1; GDSC2; CTRP2; CCLE 7.9869 12.2672 4.3643 4.0734
Hs 852.T CTRP2; CCLE 7.9925 9.4752 5.5581 0.2439
COLO 829 GDSC1; GDSC2; CTRP2 8.006 15.009 3.0729 9.0705
SK-MEL-1 GDSC1; GDSC2; CTRP2 8.0272 15.346 2.9245 9.6111
A-375 GDSC1; GDSC2; CTRP2; CCLE 8.1035 10.2242 5.3199 0.7196
Mel JuSo GDSC1; GDSC2; CTRP2 8.2646 14.1694 3.6497 6.4709
COLO 792 GDSC1; GDSC2; CTRP2 8.3127 11.3974 4.9383 1.6954
WM793 GDSC1; GDSC2; CTRP2; CCLE 8.3319 9.9814 5.5064 0.2321
Hs 839.T CTRP2 8.3605 23.3962 -0.785 21.047
LOX-IMVI GDSC1; GDSC2; CTRP2 8.5627 9.7629 5.663 0.036
Hs 944.T CTRP2; CCLE 8.6377 10.1639 5.5547 0.1093
COLO 800 GDSC1; GDSC2; CTRP2 8.665 21.3642 0.4436 17.1606
Hs 294T CTRP2; CCLE 9.7369 15.4189 3.959 3.691
Mel Ho GDSC1; GDSC2; CTRP2; CCLE 10.1531 18.4643 2.8327 7.1679
SK-MEL-5 GDSC1; GDSC2; CTRP2; CCLE 10.4758 19.4078 2.5951 7.6229
SK-MEL-3 GDSC1; GDSC2; CTRP2 11.1783 21.53 2.0465 8.6663
EquiPSC Line K2 GDSC1; GDSC2 1.9032 3.7782 1.6288 15.1803
⏷ Show the Full List of 78 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OACM5.1 C GDSC1; GDSC2 1.4728 3.2894 0.2214 3.7134
ESO-51 GDSC1; GDSC2 1.6851 6.6065 -1.2548 12.2115
ESO-26 GDSC1; GDSC2 2.5001 4.7393 0.1829 2.1127
OACP4 C GDSC1; GDSC2 2.748 5.1986 0.1163 2.1203
SK-GT-4 GDSC1; GDSC2 2.9487 6.6583 -0.4174 4.6286
KYSE-50 GDSC1; GDSC2 2.9701 4.833 0.3718 0.7948
KYAE-1 GDSC1; GDSC2 3.105 4.8304 0.4292 0.5223
FLO-1 GDSC1; GDSC2 3.1651 5.8113 0.0694 1.852
KYSE-220 GDSC1; GDSC2 3.4094 5.5254 0.2938 0.761
TE-12 GDSC1; GDSC2 3.5635 7.4348 1.4631 10.6595
HCE-4 GDSC1; GDSC2 4.2249 9.9633 0.7204 13.1986
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; GDSC2 3.4322 13.4333 -3.3247 18.1647
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KP-N-RT-BM-1 GDSC2 0.8165 3.3806 0.5714 26.4171
SJNB-7 GDSC1; GDSC2 1.8421 6.5291 -1.098 10.8926
SJNB-14 GDSC1; GDSC2 1.9408 4.9214 -0.2428 5.5132
SK-N-DZ GDSC1; GDSC2 1.9709 3.2593 0.5401 1.0284
NB(TU)1 GDSC1; GDSC2 2.0757 5.0005 -0.1905 4.9205
CHP-134 GDSC2 2.1252 3.8133 0.3834 1.6034
SK-N-BE(2)-M17 GDSC1; GDSC2 2.2009 4.0225 0.3333 1.7554
SJNB-13 GDSC1; GDSC2 2.3953 4.5523 0.2077 2.1299
GI-ME-N GDSC1; GDSC2 2.3977 5.9159 -0.4136 5.5958
SK-N-BE(2) CTRP2; CCLE 2.4704 4.8398 2.3947 24.0669
IMR-32 CCLE 2.5104 5.1149 1.5112 9.3731
SJNB-12 GDSC1; GDSC2 2.871 4.9855 0.2664 1.2916
IMR-5 GDSC1; GDSC2 3.095 5.0207 0.3533 0.7708
SJNB-17 GDSC1; GDSC2 3.142 12.0766 -1.2062 25.0623
SJNB-5 GDSC1; GDSC2 3.148 4.2678 2.6972 4.3364
GOTO GDSC1; GDSC2 3.1985 4.7929 0.4797 0.3438
NB69 GDSC1; GDSC2 3.3064 5.6144 0.215 1.1122
KP-N-YS GDSC1; GDSC2 3.3113 4.6761 2.636 4.2227
NH-12 GDSC1; GDSC2 3.3309 5.0077 0.4532 0.3529
TGW GDSC1; GDSC2 3.3313 4.9 0.4916 0.2685
SJNB-6 GDSC1; GDSC2 3.4721 5.0884 2.5605 4.2494
CHP-212 GDSC1; GDSC2; CTRP2 3.4915 5.2857 3.4228 17.2413
LA-N-6 GDSC1; GDSC2 3.5382 5.4554 2.4296 4.8767
SJNB-10 GDSC1; GDSC2 3.673 5.1 0.5445 0.1055
SK-N-AS GDSC1; GDSC2; CTRP2 3.8156 5.7327 3.6895 15.2837
SK-N-MC-IXC GDSC1; GDSC2 4.0943 5.417 2.8265 1.4269
MHH-NB-11 GDSC1; GDSC2 4.6459 7.5104 2.2013 3.9021
SK-N-FI GDSC1; GDSC2; CTRP2 6.5274 9.8328 4.5361 5.4661
CHP-126 GDSC1; GDSC2; CTRP2 7.3632 11.5421 4.3018 5.134
Kelly GDSC1; GDSC2; CTRP2 7.9871 9.4591 5.5618 0.2391
KP-N-SI9s CTRP2; CCLE 8.0848 9.5216 5.5769 0.1882
NH-6 CTRP2 8.1515 9.7919 5.505 0.2873
KP-N-YN GDSC1; GDSC2; CTRP2 8.3367 9.9867 5.5063 0.231
NB1 GDSC1; GDSC2; CTRP2 8.4322 9.7347 5.6282 0.0697
SiMa GDSC1; GDSC2; CTRP2; CCLE 8.5603 10.3536 5.4602 0.2437
SK-N-SH GDSC1; GDSC2; CTRP2; CCLE 8.8028 10.6294 5.4532 0.1971
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC1; GDSC2; CTRP2; CCLE 4.3925 7.1185 3.8664 12.942
HuH-28 CTRP2 7.7945 9.3232 5.5346 0.3602
SNU-1079 CTRP2 8.0383 15.4865 2.8642 9.8253
SNU-1196 CTRP2 8.0694 14.1082 3.5497 7.1244
SNU-478 CTRP2 8.2506 9.8791 5.512 0.2454
SNU-308 CTRP2 8.3606 9.8054 5.579 0.1275
SNU-869 CTRP2 8.4112 15.7386 2.9997 8.7651
SNU-245 CTRP2 9.2183 11.543 5.285 0.3425
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU4475 GDSC1; GDSC2; CTRP2 0.9772 2.0592 0.9772 33.7584
HCC2157 GDSC1; GDSC2 0.9881 3.3592 -0.1895 7.5652
Evsa-T GDSC1; GDSC2 1.1664 1.8781 1.1656 17.5466
OCUB-M GDSC1; GDSC2 2.389 4.005 2.0607 9.0767
CAL-120 GDSC1; GDSC2 2.6591 3.8064 2.4262 6.4471
AU565 GDSC1; GDSC2; CTRP2; CCLE 2.7354 4.0717 2.7302 22.0625
ZR-75-30 GDSC1; GDSC2; CTRP2; CCLE 2.7735 4.7176 2.7306 21.9357
UACC-893 GDSC1; GDSC2 2.7941 5.092 1.966 9.8979
COLO 824 GDSC1; GDSC2 2.9226 4.5425 2.3536 6.0016
UACC-812 GDSC2; CCLE 2.9477 5.866 1.5232 7.9137
MFM-223 GDSC1; GDSC2 3.0205 5.125 2.1583 6.7258
HCC1569 GDSC1; GDSC2; CCLE 3.0548 5.4675 2.0191 7.5444
MDA-MB-330 GDSC1; GDSC2 3.0555 5.343 2.0816 8.3632
BT-483 GDSC1; GDSC2 3.1682 5.3724 2.1659 6.3087
SK-BR-3 CCLE 3.2673 4.9819 2.222 3.5954
MDA-MB-436 GDSC1; GDSC2; CCLE 3.4331 4.8702 2.6384 3.2565
EFM-19 GDSC1; GDSC2; CCLE 3.4454 5.5371 2.3155 4.8844
MDA-MB-415 GDSC1; GDSC2; CCLE 3.5691 5.894 2.2357 5.0216
YMB-1-E GDSC2 3.5911 5.7727 2.313 5.647
CAL-148 GDSC2 3.6147 5.0068 2.7093 2.5189
MRK-nu-1 GDSC1; GDSC2 3.6299 4.9796 2.7337 2.3673
MDA-MB-175-VII GDSC1; GDSC2; CCLE 3.6894 5.5745 2.232 2.653
HCC1599 GDSC2 3.7775 5.3753 2.6456 3.1138
HCC70 GDSC1; GDSC2; CCLE 3.8244 6.5752 2.0927 5.2215
BT-20 GDSC1; GDSC2; CTRP2; CCLE 3.8763 5.5202 3.798 14.7118
HCC202 GDSC1 3.9143 6.0533 0.3011 0.5948
CAL-85-1 GDSC1; GDSC2; CTRP2; CCLE 3.9285 5.7373 3.8113 14.5004
HCC1187 GDSC1; GDSC2; CCLE 4.1705 6.4655 2.3886 3.1221
KPL-1 CTRP2 4.4323 5.9948 4.2984 11.2068
Hs 739.T CCLE 4.5571 8.3586 1.4806 5.0621
MDA-MB-157 GDSC1; GDSC2; CCLE 4.5769 6.6662 2.5436 1.8326
MDA-MB-453 GDSC1; GDSC2; CTRP2; CCLE 4.6566 7.9939 3.762 12.6569
HCC1419 GDSC1; GDSC2; CTRP2 5.5849 12.8395 2.2567 16.5642
MDA-MB-468 GDSC1; GDSC2; CTRP2; CCLE 6.8906 8.6488 5.3616 1.5892
Hs 578T GDSC1; GDSC2; CTRP2; CCLE 7.1294 12.8909 3.4779 8.8282
HCC1428 GDSC1; GDSC2; CTRP2 7.3231 13.6724 3.2364 9.4838
JIMT-1 GDSC1; GDSC2; CTRP2 7.4461 9.1224 5.4571 0.751
MDA-MB-361 GDSC1; GDSC2; CTRP2 7.5984 11.3823 4.5328 3.9052
HMC-1-8 CTRP2; CCLE 7.7647 9.0858 5.6107 0.2229
BT-474 GDSC1; GDSC2; CTRP2; CCLE 7.8139 9.2571 5.5673 0.2863
ZR-75-1 CTRP2 7.8601 9.3213 5.5621 0.2799
EFM-192A GDSC1; GDSC2; CTRP2 7.9879 14.8652 3.1298 8.8768
HCC1500 GDSC1; GDSC2; CTRP2 7.9904 15.315 2.9137 9.7078
CAL-51 GDSC1; GDSC2; CTRP2 8.0093 10.0284 5.3548 0.6821
BT-549 GDSC1; GDSC2; CTRP2; CCLE 8.0762 9.6093 5.542 0.2461
HCC2218 GDSC1; GDSC2; CTRP2 8.2032 10.4499 5.2756 0.7785
MDA-MB-231 GDSC1; GDSC2; CTRP2 8.2674 14.9198 3.2947 7.838
HCC38 GDSC1; GDSC2; CTRP2 8.3201 10.1815 5.4288 0.3721
HDQ-P1 GDSC1; GDSC2; CTRP2; CCLE 8.3694 10.2342 5.4291 0.354
HCC1937 GDSC1; GDSC2; CTRP2 8.4564 10.39 5.4065 0.3666
HCC1143 GDSC1; GDSC2; CTRP2 8.5377 12.5674 4.5516 2.7918
HCC1954 GDSC1; GDSC2; CTRP2; CCLE 8.5474 14.0079 3.9049 5.1404
HCC1806 GDSC1; GDSC2; CTRP2; CCLE 8.5621 12.263 4.6978 2.2707
HCC1395 GDSC1; GDSC2; CTRP2 8.6351 10.7949 5.3285 0.4533
T-47D GDSC1; GDSC2; CTRP2; CCLE 8.6352 10.4763 5.4448 0.2479
MCF-7 GDSC1; GDSC2; CTRP2; CCLE 8.7743 10.4249 5.5139 0.1304
CAMA-1 GDSC1; GDSC2; CTRP2; CCLE 9.258 18.8134 2.0987 10.8763
BT 131 CTRP2 2.3379 4.3837 2.3038 24.8078
BT147 CTRP2 2.4839 6.1173 2.1386 24.9199
BT 428 CTRP2 2.5939 3.1737 2.5939 22.9874
BT 248 CTRP2 2.866 4.8372 2.8156 21.3452
BT 330 CTRP2 2.9289 3.7835 2.9286 20.7568
BT 245 CTRP2 2.9888 4.624 2.9647 20.4379
BT 286 CTRP2 3.2427 5.5149 3.1134 19.1096
BT 416 CTRP2 3.4325 6.3605 3.1017 18.5701
BT 482 CTRP2 3.6035 4.7544 3.5937 16.2945
BT 422 CTRP2 3.698 5.6133 3.5873 16.0125
BT 271 CTRP2 3.804 5.1403 3.7742 15.0265
BT 440 CTRP2 3.8365 7.2164 3.2375 16.895
BT 172 CTRP2 3.8837 5.1689 3.8553 14.4908
BT 498 CTRP2 3.9249 6.3172 3.6515 15.0881
BT 504 CTRP2 4.2108 6.6475 3.8514 13.5093
BT 216 CTRP2 4.5323 7.4599 3.8708 12.5479
BT 444 CTRP2 4.6178 8.137 3.6581 13.1707
BT 320 CTRP2 4.8999 7.8164 4.0873 10.7392
BT 340 CTRP2 5.0158 7.8723 4.1768 10.0905
BT 359 CTRP2 5.6329 8.7633 4.3284 8.0484
BT 333 CTRP2 6.0696 9.3812 4.397 6.8757
BT 328 CTRP2 6.7297 9.2418 4.9745 3.3339
BT 232 CTRP2 7.1586 11.4413 4.2087 5.8094
BT 112 CTRP2 7.3483 8.4092 5.6938 0.2091
BT 139 CTRP2 7.4693 8.9816 5.5252 0.5448
BT164 CTRP2 7.5124 8.5886 5.6928 0.159
BT 159 CTRP2 7.6144 8.8058 5.6538 0.1944
BT 179 CTRP2 7.7594 8.8333 5.6983 0.096
BT 228 CTRP2 7.8191 9.0033 5.6609 0.131
BT 224 CTRP2 8.0298 9.4778 5.5716 0.2107
BT 145 CTRP2 8.2676 9.8015 5.5462 0.1886
BT 231 CTRP2 8.2779 10.2561 5.3834 0.4821
BT 187 CTRP2 8.3461 9.8336 5.5639 0.1481
BT 239 CTRP2 8.4511 9.8395 5.5995 0.0923
⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 7.2226 9.7899 5.0387 2.4211
Cancer Drug Sensitivity Data Curated from 69 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GI-1 GDSC1; GDSC2 1.8781 6.4659 -1.0401 10.4616
D-423MG GDSC1; GDSC2 2.0213 4.8906 1.299 16.5646
MOG-G-UVW GDSC1; GDSC2 2.4047 5.8691 -0.3871 5.4279
D-336MG GDSC1; GDSC2 2.4407 3.7284 2.2251 9.6775
SK-MG-1 GDSC1; GDSC2 2.4712 5.8694 -0.3451 5.0595
PFSK-1 GDSC1; GDSC2 2.5062 8.9382 -1.7946 13.1884
D-566MG GDSC1; GDSC2 2.5943 4.038 2.261 8.8664
H4 GDSC1; GDSC2; CCLE 2.8913 5.167 1.8247 6.4658
Onda 10 GDSC1; GDSC2 3.0218 4.3398 2.5454 5.6617
D-245MG GDSC2 3.0276 5.8833 1.7884 10.5927
D-263MG GDSC1; GDSC2 3.0327 4.9306 0.3611 0.7872
D-502MG GDSC1; GDSC2 3.0665 4.8021 2.3595 6.6415
CAS-1 GDSC1; GDSC2; CTRP2; CCLE 3.2056 4.2638 3.2029 18.9216
LNZTA3WT4 GDSC1 3.2144 5.0075 0.4077 0.655
KINGS-1 GDSC1; GDSC2 3.2318 5.064 0.3938 0.5568
SF126 GDSC1; GDSC2; CTRP2; CCLE 3.2782 5.0836 3.2234 18.6145
Hs 683 GDSC1; GDSC2; CTRP2; CCLE 3.2895 5.1663 3.2242 18.5751
M059J GDSC1; GDSC2; CCLE 3.3056 4.8395 2.3209 2.9056
LN-405 GDSC1; GDSC2 3.3426 4.7377 0.552 0.1572
SF268 GDSC1; GDSC2; CTRP2 3.3499 4.8872 3.3208 18.0492
AM-38 GDSC1; GDSC2 3.4505 5.7317 0.2325 0.9397
D-392MG GDSC1; GDSC2 3.4516 6.8906 -0.2403 2.9729
D-247MG GDSC1; GDSC2 3.4797 6.156 2.0341 7.438
SW1088 GDSC1; GDSC2; CTRP2; CCLE 3.5605 4.4918 3.5581 16.5561
GaMG GDSC1; GDSC2; CTRP2 3.5669 4.671 3.5597 16.5296
KNS-60 CTRP2; CCLE 3.6296 4.6924 3.5803 10.2788
D-542MG GDSC1; GDSC2 3.6539 6.3941 2.053 6.8707
KS-1 [Human Krukenberg tumour] GDSC1; GDSC2 3.7711 5.8302 0.3264 0.4765
KALS-1 GDSC1; GDSC2; CTRP2; CCLE 3.8971 5.3237 3.8512 14.461
Daoy GDSC1; GDSC2; CTRP2; CCLE 4.0513 5.8789 3.9122 13.7609
SF539 GDSC1; GDSC2; CTRP2 4.2286 5.8723 4.107 12.5184
KNS-42 GDSC1; GDSC2; CTRP2; CCLE 4.3501 5.6708 4.2823 11.5196
KNS-81-FD GDSC1; GDSC2 4.4211 6.539 2.5109 2.5903
U-251MG GDSC1; GDSC2; CTRP2 4.461 5.9815 4.3331 10.9944
GB-1 GDSC1; GDSC2; CTRP2; CCLE 4.6496 6.5016 4.3768 10.2742
MOG-G-CCM GDSC1; GDSC2; CCLE 4.8355 9.4257 1.1578 6.0415
Onda 11 GDSC1; GDSC2 5.5187 7.6931 2.5836 0.9887
TM-31 CTRP2 7.0598 8.3912 5.5702 0.6926
D283 Med GDSC1; GDSC2; CTRP2 7.1446 8.6668 5.4968 0.8582
KNS-81 CTRP2; CCLE 7.337 8.2873 5.7339 0.1416
LN-18 GDSC1; GDSC2; CTRP2; CCLE 7.3658 8.1924 5.7781 0.0737
DK-MG GDSC1; GDSC2; CTRP2; CCLE 7.3741 8.7672 5.5671 0.4892
SNU-201 CTRP2 7.4809 8.8738 5.573 0.4167
SNU-1105 CTRP2 7.603 21.6081 -0.4797 21.5148
42-MG-BA GDSC1; GDSC2; CTRP2 7.6336 10.3016 5.0489 1.9345
SNU-466 CTRP2 7.6956 8.5766 5.7632 0.0431
SW1783 GDSC1; GDSC2; CTRP2 7.6976 10.417 5.0336 1.9251
SNU-626 CTRP2 7.7214 8.8645 5.6735 0.1353
U-118MG GDSC1; GDSC2; CTRP2; CCLE 7.7408 10.7777 4.8974 2.3664
8-MG-BA GDSC1; GDSC2; CTRP2 7.7734 10.0497 5.233 1.1917
CCF-STTG1 CTRP2 7.8117 9.1296 5.6131 0.2046
YKG-1 GDSC1; GDSC2; CTRP2; CCLE 7.8956 9.309 5.5807 0.2346
SF295 GDSC1; GDSC2; CTRP2; CCLE 7.9335 9.4857 5.5308 0.3139
GMS-10 CTRP2; CCLE 7.9874 9.161 5.6672 0.0924
SNU-738 CTRP2 8.0108 9.3995 5.5924 0.1835
GOS-3 CTRP2 8.0273 9.5941 5.5284 0.2857
KG-1-C CTRP2 8.0606 9.5067 5.573 0.2002
SNU-489 CTRP2 8.1145 9.2491 5.6818 0.0619
A-172 GDSC1; GDSC2; CTRP2; CCLE 8.1282 9.6107 5.5615 0.2004
DBTRG-05MG GDSC1; GDSC2; CTRP2; CCLE 8.1874 10.0497 5.4238 0.4334
M059K CTRP2 8.2216 9.4525 5.6504 0.0758
NMC-G1 GDSC1; GDSC2; CTRP2 8.2729 9.8468 5.5321 0.208
LN-229 GDSC1; GDSC2; CTRP2; CCLE 8.2836 9.6829 5.5936 0.1242
T98G GDSC1; GDSC2; CTRP2; CCLE 8.4119 16.5699 2.6002 10.267
YH-13 GDSC1; GDSC2; CTRP2 8.4985 9.8275 5.6199 0.0691
ONS-76 GDSC1; GDSC2; CTRP2; CCLE 8.5632 10.063 5.5628 0.1122
Becker GDSC1; GDSC2; CTRP2 8.5775 10.0611 5.5685 0.1044
SNB-75 GDSC1; GDSC2; CTRP2 8.8385 10.6973 5.4426 0.2036
U-87MG ATCC GDSC1; GDSC2; CTRP2; CCLE 9.9339 19.5808 2.1781 9.7063
⏷ Show the Full List of 69 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ETK-1 GDSC1; GDSC2 1.9337 4.1138 0.1354 3.2802
TGBC1TKB GDSC1; GDSC2 2.4914 4.7703 0.1647 2.2171
TGBC24TKB GDSC1; GDSC2 2.8326 4.8449 0.3053 1.1653
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEC-1-B CCLE 2.5172 5.3787 1.3876 10.0151
HEC-151 CTRP2; CCLE 2.82 4.0157 2.8171 21.4912
EFE-184 CTRP2; CCLE 3.4492 4.3143 3.4481 17.2935
MFE-280 GDSC1; GDSC2; CCLE 3.7891 5.9942 2.0985 3.1483
KLE GDSC1; GDSC2; CCLE 4.4793 6.5512 2.253 1.4911
TEN CCLE 4.5049 8.2678 1.4898 5.1019
JHUEM-1 CTRP2 4.5191 5.601 4.4765 10.3069
HEC-1-A CTRP2; CCLE 4.576 5.6488 4.53 9.9397
EN GDSC1; GDSC2; CTRP2; CCLE 7.4413 9.5433 5.2762 1.3308
HEC-265 CTRP2; CCLE 7.4518 8.3741 5.7462 0.0962
HEC-108 CTRP2 7.6897 9.3324 5.4859 0.5231
HEC-251 CTRP2; CCLE 7.8906 9.3218 5.5741 0.2477
HEC-59 CTRP2; CCLE 7.9756 9.1013 5.6834 0.0778
RL95-2 GDSC1; GDSC2; CTRP2; CCLE 8.0599 9.4233 5.6024 0.1575
JHUEM-7 CTRP2 8.0777 9.8824 5.4413 0.4419
HEC-6 CTRP2; CCLE 8.2068 9.6997 5.5595 0.1839
AN3-CA GDSC1; GDSC2; CTRP2; CCLE 8.2743 9.9085 5.5106 0.2411
ESS-1 GDSC1; GDSC2; CTRP2 8.2975 10.0687 5.4614 0.3186
MFE-319 GDSC1; GDSC2; CTRP2 8.2979 9.6949 5.5946 0.1206
JHUEM-2 CTRP2 8.4039 10.3558 5.398 0.4017
MFE-296 GDSC1; GDSC2; CTRP2 8.5956 10.1513 5.5441 0.1267
HEC-50B CTRP2 13.7955 27.6657 0.8061 9.6766
Ishikawa (Heraklio) 02 ER- CTRP2 7.6926 9.1246 5.5672 0.3331
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LB2241-RCC GDSC1; GDSC2 0.6846 7.4813 -1.2227 33.7919
A-704 GDSC1; GDSC2 1.9725 5.5348 -0.5169 7.0994
KTCTL-140 GDSC1; GDSC2 2.3271 3.2873 2.2455 10.0514
UO-31 GDSC1; GDSC2; CTRP2 2.3973 3.345 2.3971 24.2984
SW156 GDSC1; GDSC2 2.899 4.5844 2.311 7.4784
NCC010 GDSC1; GDSC2 2.91 4.7698 2.2314 7.9201
A-498 GDSC1; GDSC2 3.0284 4.5282 0.5096 0.3421
KTCTL-13 GDSC1; GDSC2 3.0542 4.7108 2.3934 6.4748
SW13 GDSC1; GDSC2 3.1534 5.081 0.355 0.7254
LB996-RCC GDSC2 3.2532 6.089 -0.0026 2.0821
KTCTL-195 GDSC1; GDSC2 3.273 5.0621 0.411 0.4863
SN12C GDSC1; GDSC2 3.5768 5.2002 0.4767 0.2233
NCC021 GDSC1; GDSC2 3.6115 5.2045 2.6097 3.6053
HA7-RCC GDSC1; GDSC2 3.6277 5.2986 2.5754 3.7733
CAL-54 GDSC1; GDSC2; CTRP2 3.6449 5.0196 3.6185 16.0746
TUHR14TKB CTRP2 3.6944 7.4039 3.0131 18.1466
KTCTL-26A GDSC1; GDSC2 3.8194 5.597 2.5676 3.3875
TK-10 GDSC1; GDSC2 3.8559 6.2125 0.2198 0.7257
KTCTL-21 GDSC1; GDSC2 3.8854 6.7913 2.0315 6.4366
KTCTL-1M GDSC1; GDSC2 4.301 6.6446 2.3885 3.4716
VMRC-RCZ GDSC1; GDSC2; CTRP2; CCLE 4.3468 5.5656 4.2971 11.4788
BFTC-909 GDSC1; GDSC2; CTRP2; CCLE 4.4757 5.1485 4.4721 10.4628
KMRC-2 CTRP2; CCLE 4.4788 7.4559 3.8169 12.9012
LB1047-RCC GDSC1; GDSC2 4.5066 7.0612 2.3232 3.4707
RXF 393L GDSC1; GDSC2 4.9066 10.034 1.1771 9.1363
BB65-RCC GDSC1; GDSC2 5.3291 15.2832 -1.0795 18.9716
TUHR10TKB CTRP2 7.4074 8.538 5.6698 0.2343
KMRC-1 GDSC1; GDSC2; CTRP2; CCLE 7.8499 9.0379 5.6601 0.1255
KMRC-20 GDSC1; GDSC2; CTRP2 7.9992 10.156 5.2992 0.8368
786-O GDSC1; GDSC2; CTRP2; CCLE 8.0113 12.82 4.1219 4.9733
TUHR4TKB CTRP2 8.0465 9.2595 5.6544 0.0966
RCC10RGB GDSC1; GDSC2; CTRP2 8.1939 9.4491 5.6418 0.0874
SNU-1272 CTRP2 8.2174 9.663 5.5763 0.1584
Caki-2 CTRP2; CCLE 8.2276 9.4815 5.6426 0.082
OS-RC-2 GDSC1; GDSC2; CTRP2 8.3123 10.1349 5.4429 0.3477
ACHN GDSC1; GDSC2; CTRP2 8.33 9.8323 5.5585 0.1582
VMRC-RCW GDSC1; GDSC2; CTRP2; CCLE 8.4341 10.0898 5.5065 0.2063
KMRC-3 CTRP2 8.4905 10.2134 5.4837 0.2259
769-P GDSC1; GDSC2; CTRP2; CCLE 8.661 10.0295 5.608 0.0617
Caki-1 GDSC1; GDSC2; CTRP2 9.1509 10.9842 5.456 0.1327
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 60 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW1463 GDSC1; GDSC2 2.4046 3.948 0.4671 0.895
GP5d GDSC1; GDSC2 2.4924 4.2361 0.3916 1.1302
COLO 320 CTRP2; CCLE 2.6435 4.7224 2.5928 22.8283
CL-11 GDSC1; GDSC2; CTRP2 2.6702 5.3545 2.5249 22.977
C2BBe1 GDSC1; GDSC2; CCLE 2.6899 5.3195 1.5726 8.3123
SW837 GDSC1; GDSC2 2.8579 4.8422 0.3181 1.0898
SW1116 GDSC1; GDSC2; CTRP2 2.9007 4.8832 2.847 21.1254
NCI-H747 GDSC1; GDSC2; CTRP2; CCLE 3.0184 4.4604 3.0055 20.203
SNU-C5 GDSC1; GDSC2; CTRP2 3.0655 5.4883 2.9266 20.3231
COLO 320HSR GDSC1; GDSC2 3.1073 9.0549 -1.4356 9.9508
DiFi GDSC1; GDSC2 3.1724 5.1074 0.353 0.7198
SNU-175 GDSC2 3.1814 5.0718 0.3702 0.6582
SNU-C2B GDSC1; GDSC2; CCLE 3.2226 5.1683 2.0954 4.2577
SW626 GDSC1; GDSC2 3.3029 6.0416 0.0415 1.8301
HCC2998 GDSC1; GDSC2 3.7382 5.5357 0.4187 0.2838
CaR-1 GDSC1; GDSC2 3.8496 5.7903 0.3704 0.3452
SW403 CCLE 4.3484 6.8858 2.0326 2.6865
SNU-81 GDSC1; GDSC2 4.6435 20.2798 -4.0824 29.4171
SW480 CCLE 5.4128 8.4931 1.9082 1.9806
SNU-283 GDSC2 5.5049 7.0786 2.8087 0.3333
OUMS-23 CTRP2 6.9814 9.5736 4.9863 2.9308
SW948 GDSC1; GDSC2; CTRP2 7.575 8.7354 5.664 0.1887
HCC-56 CTRP2; CCLE 7.6474 8.5937 5.7407 0.0686
COLO201 CTRP2; CCLE 7.6718 8.9504 5.6235 0.2296
LS1034 GDSC1; GDSC2; CTRP2 7.7476 9.5273 5.435 0.6217
DLD-1 CTRP2 7.7644 8.8818 5.6833 0.1132
SNU-1033 CTRP2 7.7705 10.4228 5.0713 1.7254
COLO205 GDSC1; GDSC2; CTRP2; CCLE 7.7961 9.0421 5.6385 0.1683
HCT 8 CTRP2 7.8019 9.0505 5.6378 0.168
SNU-503 CTRP2 7.8089 11.9207 4.4143 4.0993
T84 GDSC1; GDSC2; CTRP2; CCLE 7.864 9.8521 5.3586 0.7573
HCT 116 GDSC1; GDSC2; CTRP2; CCLE 7.892 13.1208 3.9022 5.9871
RCM-1 [Human ESC] GDSC1; GDSC2; CTRP2 7.9225 9.588 5.4878 0.407
HT115 GDSC1; GDSC2; CTRP2 7.9284 9.0676 5.6782 0.09
SNU-C4 CTRP2 7.9434 8.9516 5.7227 0.0484
HT-29 GDSC1; GDSC2; CTRP2; CCLE 7.9625 9.4556 5.5535 0.2614
KM12 GDSC1; GDSC2; CTRP2 7.9839 9.5382 5.5316 0.2943
NCI-H508 GDSC1; GDSC2; CTRP2 8.0103 9.5057 5.5539 0.2456
LS180 GDSC1; GDSC2; CTRP2 8.098 9.8318 5.4687 0.3757
COLO 678 GDSC1; GDSC2; CTRP2; CCLE 8.1073 10.0125 5.4041 0.5118
LS411N GDSC1; GDSC2; CTRP2 8.1141 9.6135 5.5552 0.2139
HCT 15 GDSC1; GDSC2; CTRP2; CCLE 8.2148 9.6331 5.5859 0.1465
HT-55 GDSC1; GDSC2; CTRP2 8.2249 9.3152 5.6974 0.0406
NCI-H716 GDSC1; GDSC2; CTRP2 8.2562 9.8874 5.5112 0.2452
GP2d CTRP2 8.2629 9.867 5.521 0.2276
MDST8 GDSC1; GDSC2; CTRP2 8.2717 9.5496 5.635 0.0833
CW-2 GDSC1; GDSC2; CTRP2 8.2849 10.0426 5.4659 0.3144
LS123 GDSC1; GDSC2; CTRP2; CCLE 8.3229 10.2109 5.419 0.3902
SK-CO-1 GDSC1; GDSC2; CTRP2; CCLE 8.3328 9.7284 5.5955 0.1138
SNU-61 GDSC1; GDSC2; CTRP2 8.3331 9.9224 5.5279 0.1994
SNU-C2A CTRP2; CCLE 8.3794 11.8891 4.762 2.2184
CCK-81 GDSC1; GDSC2; CTRP2 8.5018 10.086 5.5328 0.1564
SW48 GDSC1; GDSC2; CTRP2; CCLE 8.5271 10.1361 5.5246 0.1617
SNU-C1 GDSC1; GDSC2; CTRP2 8.5967 15.7503 3.1182 8.0595
SW620 GDSC1; GDSC2; CTRP2; CCLE 8.655 10.0368 5.6036 0.0654
LoVo GDSC1; GDSC2; CTRP2 8.7027 10.6299 5.4155 0.2755
LS513 GDSC1; CTRP2; CCLE 8.7282 10.6292 5.4255 0.2535
SW1417 GDSC1; GDSC2; CTRP2 8.852 10.4676 5.5267 0.1064
SNU-407 GDSC1; GDSC2; CTRP2 8.9813 11.0304 5.3782 0.2609
RKO GDSC1; GDSC2; CTRP2; CCLE 10.7701 21.9864 1.5834 10.6465
⏷ Show the Full List of 60 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1; GDSC2 2.2616 6.5044 -0.7849 8.0595
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-182 CTRP2; CCLE 2.1406 5.3901 1.9432 26.6816
JHH-5 CTRP2 2.5002 3.7814 2.4975 23.6211
Huh-7 GDSC1; GDSC2 2.6738 5.0777 0.1292 2.1518
Hep-G2/C3A GDSC1; GDSC2 2.7272 3.9019 0.619 0.208
Li-7 CTRP2 2.7407 5.4871 2.5744 22.5811
HuH-6 CTRP2 2.8119 5.3974 2.67 22.0219
SNU-449 GDSC1; GDSC2; CTRP2; CCLE 3.2108 4.7979 3.1828 18.972
JHH-7 GDSC1; GDSC2 3.3895 5.7132 0.2132 1.0538
SNU-761 CTRP2 3.46 4.0965 3.4575 11.3177
SNU-886 CTRP2 3.9299 5.1868 3.9022 14.1804
HLE GDSC1; GDSC2; CCLE 5.6289 7.8965 2.2451 0.6501
JHH-6 GDSC1; GDSC2; CTRP2; CCLE 6.7599 8.3119 5.4369 1.4577
JHH-2 GDSC1; GDSC2; CTRP2; CCLE 7.2648 10.1695 4.8886 2.946
JHH-4 GDSC1; GDSC2; CTRP2; CCLE 7.4493 10.1832 4.9955 2.3222
PLC/PRF/5 CTRP2; CCLE 7.5483 9.2803 5.4416 0.7265
SK-HEP-1 GDSC1; GDSC2; CTRP2; CCLE 7.5922 16.3312 2.1271 13.3
SNU-387 GDSC1; GDSC2; CTRP2 7.7177 11.401 4.5989 3.5034
Hep 3B2.1-7 GDSC1; GDSC2; CTRP2; CCLE 7.8 13.8143 3.5074 7.6741
JHH-1 GDSC1; GDSC2; CTRP2 7.9183 9.0418 5.6835 0.0861
HuH-1 GDSC1; GDSC2; CTRP2; CCLE 8.0044 9.4856 5.5589 0.2389
HLF CTRP2; CCLE 8.2811 9.5704 5.6312 0.0855
SNU-423 GDSC1; GDSC2; CTRP2; CCLE 8.4273 10.2728 5.4379 0.3187
SNU-398 GDSC1; GDSC2; CTRP2 8.4756 10.2228 5.4747 0.2434
SNU-878 CTRP2 8.5206 10.27 5.4749 0.2315
SNU-475 CTRP2 8.587 9.9425 5.6118 0.0661
Hep-G2 CTRP2; CCLE 10.7093 26.8422 -0.7703 17.5497
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 225 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1703 GDSC1; GDSC2; CTRP2 0.666 4.2559 0.5489 36.1988
NCI-H835 GDSC1; GDSC2 1.5771 3.5717 0.1576 3.871
CPC-N GDSC1; GDSC2 1.741 4.8326 -0.3393 6.5461
NCI-H1304 GDSC1 1.7458 3.4738 0.3156 3.2188
Ms-1 GDSC1; GDSC2 1.7646 4.62 -0.2192 5.756
COR-L279 GDSC1; GDSC2 1.7819 3.7563 0.2063 3.1547
NCI-H720 GDSC1; GDSC2 1.8646 3.4462 0.4002 1.9
Lu-139 GDSC1 2.0366 4.2112 0.154 3.7196
NCI-H524 GDSC1; GDSC2 2.0463 5.2778 -0.3423 5.8869
NCI-H64 GDSC1; GDSC2 2.0715 4.3075 0.1309 3.0565
DMS 454 CTRP2 2.0887 4.7752 1.9961 26.6669
RERF-LC-Sq1 GDSC1; GDSC2 2.0953 5.0717 -0.2114 5.0048
Lu-135 GDSC1; GDSC2 2.1077 4.4882 0.0698 3.3406
A-427 GDSC1; GDSC2 2.1681 5.9381 0.961 17.954
NCI-H2795 GDSC1; GDSC2 2.2036 4.4189 0.1589 2.6781
DMS 53 GDSC1; GDSC2; CTRP2 2.214 3.0813 2.214 25.5186
NCI-H2171 GDSC2 2.2147 3.3121 2.1162 11.6295
NCI-H211 GDSC1; GDSC2; CTRP2; CCLE 2.2528 4.3762 2.2154 25.3858
NCI-H1648 GDSC1; GDSC2; CCLE 2.3545 4.1087 1.8458 7.8536
NCI-H1385 CTRP2 2.3919 3.7646 2.3883 24.3452
NCI-H146 GDSC1; GDSC2; CTRP2 2.4049 4.7749 2.3335 24.4885
NCI-H1688 GDSC1; GDSC2 2.4649 4.3215 0.3428 1.3791
NCI-H2029 GDSC1; GDSC2 2.4651 4.7482 1.8109 11.9593
COR-L311 GDSC2 2.4854 6.1634 -0.4737 5.7746
SK-MES-1 GDSC1; GDSC2; CTRP2 2.5233 3.4157 2.5232 23.4584
NCI-H3122 GDSC1; GDSC2 2.5242 5.9939 -0.3699 5.1035
NCI-H2087 GDSC1; GDSC2; CTRP2; CCLE 2.6261 5.2847 2.4905 23.2368
NCI-H1781 GDSC1; GDSC2 2.6482 4.0798 0.5229 0.5013
COLO 677 CCLE 2.679 5.278 1.5836 8.5121
NCI-H1993 GDSC1; GDSC2 2.7229 5.1377 0.1292 2.0887
NCI-H2461 GDSC1; GDSC2 2.7989 5.4828 0.0207 2.53
NCI-H810 GDSC1; GDSC2; CTRP2; CCLE 2.8131 4.3437 2.7997 21.5723
COR-L303 GDSC2 2.8544 4.999 2.0678 9.4123
DV-90 CTRP2 2.9217 5.7419 2.7141 21.5225
NCI-H2369 GDSC1; GDSC2 2.9756 4.4886 0.5034 0.3815
NCI-H2804 GDSC1; GDSC2 2.9858 4.5036 2.432 6.4632
NCI-H209 GDSC1; GDSC2 2.9888 5.1825 0.2421 1.2811
RERF-LC-KJ GDSC1; GDSC2 2.992 4.4808 0.5127 0.3503
NCI-H187 GDSC1 3.0074 4.1262 0.6421 0.1223
NCI-H1155 GDSC1; GDSC2; CTRP2 3.011 4.4309 2.9993 20.248
NCI-H1048 GDSC1; GDSC2; CCLE 3.0376 4.4791 2.2916 3.6455
NCI-H1437 GDSC1; GDSC2 3.0508 4.401 2.5426 5.5838
HCC2935 CTRP2; CCLE 3.0718 4.0389 3.0708 19.8071
IST-SL1 GDSC1; GDSC2 3.1011 5.2324 2.1769 7.6442
LC-1/sq GDSC1; GDSC2 3.1391 5.7667 0.0751 1.8546
COLO 668 GDSC1; GDSC2; CTRP2 3.1419 5.5122 3.0046 19.8088
LB647-SCLC GDSC1; GDSC2 3.1667 4.2032 2.7461 3.9809
NCI-H2373 GDSC1; GDSC2 3.1755 5.0311 0.3831 0.6213
NCI-H82 GDSC1; GDSC2 3.1758 4.7269 0.4947 0.3176
NCI-H2810 GDSC1; GDSC2 3.211 4.5459 2.6152 4.6417
ABC-1 GDSC1; GDSC2 3.215 4.7825 2.5007 5.3278
NCI-H1581 GDSC1; GDSC2; CTRP2; CCLE 3.2218 4.907 3.1841 18.9317
NCI-H358 GDSC1; GDSC2; CTRP2; CCLE 3.2276 4.4747 3.2197 18.7924
Calu-3 GDSC1; GDSC2; CTRP2; CCLE 3.2286 4.2219 3.2268 18.7654
NCI-H1573 GDSC1; GDSC2; CTRP2; CCLE 3.2407 6.5669 2.8275 20.1456
Lu-165 GDSC1; GDSC2 3.2417 4.5647 0.5754 0.1442
NCI-H2066 GDSC1; GDSC2 3.2474 4.9128 0.4553 0.3824
HCC44 GDSC1; GDSC2; CTRP2 3.2553 5.3691 3.1548 18.9246
NCI-H2106 CTRP2 3.2664 4.7791 3.2425 18.5878
NCI-H1694 GDSC1; GDSC2; CTRP2; CCLE 3.2744 5.0084 3.2286 18.6088
HCC33 GDSC2 3.2954 4.5707 2.6753 4.1717
LK-2 GDSC1; GDSC2 3.299 5.0395 0.4295 0.4249
HARA [Human squamous cell lung carcinoma] GDSC1; GDSC2; CTRP2 3.3104 4.7108 3.2931 18.2724
NCI-H1355 GDSC1; GDSC2; CTRP2; CCLE 3.3204 4.2897 3.3185 18.1539
NCI-H1793 GDSC1; GDSC2; CTRP2; CCLE 3.3283 4.3259 3.326 18.1025
NCI-H1963 GDSC1; GDSC2 3.3436 4.8937 0.4984 0.2509
NCI-H1623 GDSC1; GDSC2 3.3447 5.1592 0.4038 0.4708
SBC-3 GDSC1; GDSC2 3.3455 5.0476 0.4445 0.3676
NCI-H522 GDSC2; CTRP2; CCLE 3.3498 4.701 3.3346 18.0028
NCI-H2818 GDSC1; GDSC2 3.364 5.3149 0.3541 0.601
IA-LM GDSC1; GDSC2; CCLE 3.4212 4.8405 2.4028 2.2638
HCC15 GDSC1; GDSC2; CTRP2; CCLE 3.4248 5.2938 3.3499 17.7071
Lu-134-A GDSC1; GDSC2 3.4316 5.9659 2.0901 7.2259
NCI-H1693 GDSC1; GDSC2; CTRP2; CCLE 3.4356 5.6449 3.2957 17.8623
NCI-H847 GDSC1; GDSC2 3.4664 4.8897 0.5438 0.1428
Calu-1 CTRP2; CCLE 3.4892 4.6193 3.482 17.0471
NCI-H596 GDSC1; GDSC2 3.4924 5.226 0.4366 0.3293
NCI-H1944 GDSC1; GDSC2; CTRP2; CCLE 3.4973 4.702 3.4869 17.004
HCC1171 CTRP2 3.5172 4.8882 3.4959 16.9081
NCI-H1666 GDSC1; GDSC2; CTRP2; CCLE 3.5175 5.8474 3.3379 17.4583
NCI-H2722 GDSC1; GDSC2 3.524 4.9358 0.5483 0.1256
NCI-H1876 GDSC1; GDSC2 3.5243 4.9235 0.5526 0.1202
ChaGo-K-1 GDSC1; GDSC2; CTRP2 3.5335 6.1883 3.2636 17.677
NCI-H345 GDSC1; GDSC2 3.5641 5.8949 2.2313 6.0163
UMC-11 GDSC1; GDSC2 3.6034 5.4387 0.4027 0.3634
NCI-H250 GDSC2 3.6168 6.1849 2.1281 6.7416
NCI-H513 GDSC1; GDSC2 3.6807 5.6063 0.3722 0.4034
NCI-H322M GDSC1; GDSC2 3.6832 7.5374 -0.3963 3.4386
HCC4006 CTRP2; CCLE 3.6921 5.0411 3.6661 15.7588
NCI-H2869 GDSC1; GDSC2 3.6927 5.8527 2.3507 4.9736
COR-L23 GDSC1; GDSC2; CCLE 3.7144 5.5962 2.2381 2.5815
Lu-99 CTRP2; CCLE 3.734 5.5378 3.641 15.7106
PaCa-3 GDSC1; GDSC2 3.7928 5.8281 0.3355 0.4451
NCI-H290 GDSC1; GDSC2 3.8187 8.3217 1.223 11.4004
NCI-H1092 GDSC1; GDSC2; CCLE 3.8899 6.8078 1.777 4.5853
NCI-H1975 GDSC1; GDSC2; CCLE 3.9083 6.4173 1.9761 3.5549
NCI-H1836 GDSC1; GDSC2 3.9134 5.6686 2.5974 3.0181
NCI-H1650 GDSC1; GDSC2; CTRP2; CCLE 3.9199 5.6536 3.8196 14.4984
NCI-H2591 GDSC1; GDSC2 4.0024 6.4622 0.1863 0.7436
EMC-BAC-2 GDSC1; GDSC2 4.038 5.8487 0.4185 0.2046
NCI-H2595 GDSC1; GDSC2 4.045 5.8184 0.4313 0.1841
NCI-H1436 GDSC1; GDSC2 4.0457 5.929 2.5609 2.9692
LC-2/ad GDSC1; GDSC2 4.046 6.227 2.4195 3.784
RERF-LC-A1 CTRP2; CCLE 4.0569 5.4895 3.9978 13.4426
NCI-H647 GDSC1; GDSC2; CTRP2; CCLE 4.0842 5.7463 3.9786 13.4234
SBC-1 GDSC1; GDSC2 4.0918 8.169 1.5063 9.0702
NCI-H2731 GDSC1; GDSC2 4.1513 6.0421 0.3925 0.219
KNS-62 GDSC1; GDSC2; CTRP2 4.1656 5.3898 4.1286 12.6419
NCI-H2135 GDSC1; GDSC2 4.1662 5.8208 2.6863 2.0579
NCI-H3255 GDSC1; GDSC2; CCLE 4.1667 5.9664 2.6198 2.0873
NCI-H1915 GDSC1; GDSC2; CTRP2; CCLE 4.2362 5.905 4.1074 12.4937
Lu-99A GDSC1; GDSC2 4.2383 6.3348 0.3228 0.3162
NCI-H1563 GDSC1; GDSC2; CTRP2; CCLE 4.2466 5.3905 4.2147 12.0852
LUDLU-1 CTRP2; CCLE 4.2484 6.8515 3.8171 13.5317
NCI-H2444 GDSC1; GDSC2; CTRP2; CCLE 4.2508 5.251 4.1142 6.1883
EMC-BAC-1 GDSC1; GDSC2 4.3204 9.2095 1.1631 10.5114
NCI-H2347 GDSC1; GDSC2 4.3231 6.273 0.3745 0.2081
NCI-H2803 GDSC1; GDSC2 4.3233 8.3641 1.5788 8.1136
NCI-H2170 GDSC1; GDSC2; CTRP2; CCLE 4.4008 5.3197 4.3847 11.0042
Sq-1 CTRP2 4.416 8.6791 3.2077 15.4773
NCI-H1770 GDSC1; GDSC2 4.4167 6.0548 2.7239 1.497
LCLC-97TM1 GDSC1; GDSC2; CTRP2 4.4342 5.9579 4.31 11.1597
IST-SL2 GDSC1; GDSC2 4.4711 8.1097 1.8048 5.4569
SW900 CCLE 4.5887 6.7664 2.2179 1.5613
COR-L32 GDSC2 4.5917 8.1494 1.8668 4.952
COR-L321 GDSC1; GDSC2 4.6212 8.4333 1.7511 6.4881
HOP-62 GDSC1; GDSC2; CTRP2 4.7919 6.7749 4.4265 9.6839
NCI-H446 GDSC1; GDSC2; CTRP2 4.8091 9.566 3.1718 14.6664
NCI-H748 GDSC2 4.9673 7.2791 2.4879 2.0068
NCI-H2228 GDSC1; GDSC2; CTRP2; CCLE 5.0291 8.1729 4.0491 10.5763
NCI-H1105 GDSC1; GDSC2; CTRP2 5.0944 8.8146 3.8053 11.4184
GLC-82 CCLE 5.2267 8.4614 1.8257 2.5169
NCI-H740 GDSC2 5.3558 9.8438 1.5599 6.3871
Hs 229.T CCLE 5.3733 8.227 1.9993 1.6633
SBC-5 GDSC1; GDSC2; CTRP2; CCLE 5.662 7.576 4.9405 5.4352
NCI-H2227 GDSC1; GDSC2 5.7923 7.7772 2.6669 0.5504
NCI-H510A GDSC1; GDSC2 5.8072 7.3744 2.8167 0.2088
NCI-H2141 GDSC1; GDSC2; CTRP2 6.1453 10.5279 3.8862 8.8722
NCI-H520 GDSC1; GDSC2; CTRP2; CCLE 6.1684 9.5735 4.3821 6.751
NCI-H1568 GDSC1; GDSC2; CTRP2; CCLE 6.9763 10.9207 3.5175 3.757
A-549 GDSC1; GDSC2; CTRP2; CCLE 7.0959 10.6791 4.534 4.5827
MOR/CPR CTRP2 7.1563 8.2283 5.6819 0.3168
BEN GDSC1; GDSC2; CTRP2 7.2319 8.7245 5.5168 0.7265
RERF-LC-Ad1 CTRP2 7.2578 8.1022 5.7699 0.1067
NCI-H526 GDSC1; GDSC2; CTRP2 7.3498 8.8118 5.538 0.5832
HCC95 CTRP2 7.4783 9.2411 5.4238 0.8274
EKVX GDSC1; GDSC2; CTRP2 7.5228 11.4341 4.4596 4.289
NCI-H226 GDSC1; GDSC2; CTRP2; CCLE 7.5781 8.9906 5.5699 0.3771
HCC1195 CTRP2 7.6313 11.8075 4.3537 4.5617
NCI-H2085 GDSC1; GDSC2; CTRP2; CCLE 7.6422 16.1119 2.2723 12.6824
NCI-H460 GDSC1; GDSC2; CTRP2 7.6522 8.7748 5.6794 0.1433
NCI-H1341 GDSC1; GDSC2; CTRP2; CCLE 7.7163 9.1583 5.5643 0.3295
COR-L95 GDSC1; CTRP2 7.7171 9.2409 5.5333 0.3966
NCI-H2081 GDSC1; GDSC2; CTRP2 7.733 14.8773 2.9439 9.9851
Lu-65 GDSC1; GDSC2; CTRP2 7.7333 10.3087 5.1009 1.6589
VMRC-LCD GDSC1; GDSC2; CTRP2; CCLE 7.7509 9.8683 5.2977 1.0091
HCC827 GDSC1; GDSC2; CTRP2 7.798 10.034 5.252 1.1135
SHP-77 GDSC1; GDSC2; CTRP2; CCLE 7.8578 9.2244 5.5966 0.2186
COR-L88 GDSC1; GDSC2; CTRP2 7.8585 9.8109 5.3726 0.7225
NCI-H2126 CTRP2 7.8731 9.1329 5.6353 0.1542
NCI-H2122 GDSC1; GDSC2; CTRP2; CCLE 7.8885 9.1294 5.6422 0.141
DMS 114 GDSC1; GDSC2; CTRP2; CCLE 7.9179 10.2729 5.212 1.1462
NCI-H2196 GDSC2; CTRP2 7.9296 9.6325 5.4739 0.4347
DMS 273 GDSC1; GDSC2; CTRP2 7.9316 9.4327 5.5496 0.2787
LCLC-103H GDSC1; GDSC2; CTRP2; CCLE 7.9583 9.1669 5.6547 0.1112
NCI-H23 GDSC1; GDSC2; CTRP2; CCLE 7.9648 10.2194 5.2571 0.9785
COR-L105 GDSC1; GDSC2; CTRP2 8.0275 12.4012 4.3274 4.1649
NCI-H1395 CTRP2 8.0748 10.6328 5.1399 1.2496
NCI-H838 GDSC1; GDSC2; CTRP2 8.0883 9.2633 5.6679 0.0771
NCI-H322 CTRP2; CCLE 8.0888 14.104 3.5647 7.0388
HCC78 GDSC1; GDSC2; CTRP2; CCLE 8.1283 9.5243 5.5922 0.1564
DMS 79 GDSC1; GDSC2; CTRP2 8.1305 10.1094 5.3767 0.5645
LC-1/sq-SF CTRP2; CCLE 8.1585 9.389 5.6498 0.0846
HCC1438 CTRP2 8.1625 9.6313 5.5671 0.1835
NCI-H1339 CTRP2; CCLE 8.1961 9.5418 5.6108 0.1198
NCI-H2286 CTRP2; CCLE 8.1981 9.6274 5.5817 0.1553
NCI-H196 GDSC1; GDSC2; CTRP2 8.2002 10.5741 5.2245 0.9175
NCI-H2009 GDSC1; GDSC2; CTRP2; CCLE 8.2413 9.9451 5.4844 0.2953
NCI-H2342 GDSC1; GDSC2; CTRP2 8.2509 10.7507 5.1768 1.0183
T3M-10 CTRP2; CCLE 8.2595 10.0911 5.4378 0.3765
CAL-12T GDSC1; GDSC2; CTRP2 8.2907 9.9166 5.5139 0.2313
Calu-6 GDSC1; GDSC2; CTRP2 8.3044 11.2437 4.999 1.5099
HCC2108 CTRP2 8.3196 10.3017 5.3836 0.4642
SK-LU-1 GDSC1; GDSC2; CTRP2; CCLE 8.3375 10.3025 5.3907 0.4419
PC-14 GDSC1; GDSC2; CTRP2 8.374 10.0647 5.4926 0.2424
SW1271 GDSC1; GDSC2; CTRP2; CCLE 8.3796 12.8757 4.3229 3.7759
NCI-H650 GDSC1; GDSC2; CTRP2; CCLE 8.3961 10.046 5.5077 0.2137
LOU-NH91 GDSC1; GDSC2; CTRP2; CCLE 8.4197 10.0499 5.5152 0.1972
NCI-H2291 GDSC1; GDSC2; CTRP2 8.4228 12.618 4.4643 3.2152
HCC1588 CTRP2 8.4477 17.0445 2.3956 10.9702
NCI-H1435 GDSC1; GDSC2; CTRP2 8.463 9.7544 5.6322 0.0634
LXF 289 GDSC1; GDSC2; CTRP2 8.4767 12.0238 4.7557 2.1529
NCI-H2172 GDSC1; GDSC2; CTRP2; CCLE 8.4836 10.0422 5.5414 0.1493
NCI-H1838 GDSC1; GDSC2; CTRP2 8.4992 11.8789 4.8297 1.8913
NCI-H1734 GDSC1; GDSC2; CTRP2 8.5073 10.3362 5.4461 0.2804
NCI-H2030 GDSC1; GDSC2; CTRP2; CCLE 8.5225 10.1815 5.507 0.1854
COLO 699 CTRP2; CCLE 8.5254 14.1795 3.8117 5.5187
NCI-H1651 GDSC1; GDSC2; CTRP2; CCLE 8.5307 10.7083 5.3179 0.5166
EBC-1 GDSC1; GDSC2; CTRP2; CCLE 8.5327 10.3285 5.4587 0.2533
NCI-H69 GDSC1; GDSC2; CTRP2 8.5438 10.4116 5.433 0.2917
NCI-H1184 CTRP2; CCLE 8.5463 10.1746 5.5182 0.1659
HCC366 GDSC1; GDSC2; CTRP2 8.5734 10.3547 5.4647 0.2335
NCI-H1869 GDSC1; GDSC2; CTRP2; CCLE 8.5778 10.6542 5.3575 0.4172
NCI-H1373 CTRP2; CCLE 8.6262 13.9714 3.97 4.8041
NCI-H2023 GDSC1; GDSC2; CTRP2; CCLE 8.6369 10.2952 5.5092 0.1595
RERF-LC-MS GDSC1; GDSC2; CTRP2; CCLE 8.6411 10.2592 5.5232 0.1423
NCI-H292 GDSC1; GDSC2; CTRP2 8.6595 10.268 5.5268 0.1351
NCI-H1755 GDSC1; GDSC2; CTRP2 8.6965 10.4432 5.4793 0.1851
EPLC-272H GDSC1; GDSC2; CTRP2 8.7603 10.4325 5.5062 0.141
NCI-H2405 GDSC1; GDSC2; CTRP2 8.7646 10.7388 5.4001 0.2831
NCI-H441 GDSC1; GDSC2; CTRP2; CCLE 8.7734 10.232 5.5789 0.0719
SW1573 GDSC1; GDSC2; CTRP2 8.8409 17.2299 2.5756 9.7456
NCI-H727 GDSC1; GDSC2; CTRP2; CCLE 8.8539 10.7369 5.4344 0.2112
RERF-LC-Ad2 CTRP2 8.8562 10.3984 5.5515 0.0844
NCI-H1792 GDSC1; GDSC2; CTRP2; CCLE 8.8634 10.3964 5.5547 0.081
NCI-H1299 GDSC1; GDSC2; CTRP2 8.8665 10.5053 5.519 0.1117
HOP-92 GDSC1; GDSC2; CTRP2 9.0838 11.394 5.2868 0.3786
NCI-H2110 GDSC1; GDSC2; CTRP2 9.0868 11.323 5.3137 0.3328
HCC2279 CTRP2 9.1224 11.018 5.4343 0.16
NCI-H661 GDSC1; GDSC2; CTRP2; CCLE 9.1456 11.1569 5.3946 0.2026
NCI-H889 CTRP2 9.3938 23.4082 -0.0292 17.4207
LK2 CTRP2 9.8009 24.5231 -0.2823 17.5265
NCI-H841 GDSC1; GDSC2; CTRP2 10.2559 18.3154 2.9619 6.6036
HCC1833 CTRP2 11.6301 24.7408 0.8401 11.9119
Hs 888.Lu CTRP2 8.4961 9.9096 5.5914 0.0938
⏷ Show the Full List of 225 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1; GDSC2 3.2728 5.2177 0.3531 0.6565
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 6.915 7.8195 5.7349 0.3124
P-STS CTRP2 7.9394 9.3764 5.5733 0.2339
SYO-1 CTRP2 8.284 10.0012 5.4807 0.2884
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 7.2883 8.5887 5.599 0.4548
Aska-SS CTRP2 7.4944 9.2237 5.4389 0.7712
A-204 GDSC1; GDSC2; CTRP2; CCLE 1.1499 4.775 0.9882 33.1359
EW-8 GDSC1; GDSC2 1.4741 3.2445 0.2441 3.5711
G-402 GDSC1; GDSC2; CTRP2 1.833 6.1983 1.4055 29.4999
TE 441.T GDSC2; CTRP2 2.3753 3.1296 2.3753 24.4441
SW684 GDSC1; GDSC2 2.8638 3.9257 0.6599 0.1015
Hs 633.T GDSC1; GDSC2 2.9549 4.7686 0.3901 0.7415
VA-ES-BJ GDSC1; GDSC2 3.151 7.2179 -0.5519 5.0289
MES-SA GDSC1; GDSC2; CCLE 3.1756 4.8611 2.2114 3.7521
Hs 729.T CTRP2 3.2318 5.1003 3.1717 18.9415
Rh30 GDSC1; GDSC2; CCLE 3.3051 5.4724 2.008 4.5371
MFH-ino GDSC1; GDSC2 3.3126 5.4206 0.2929 0.8277
SW872 GDSC1; GDSC2 3.4682 5.1619 0.4502 0.3085
GCT GDSC1; GDSC2; CTRP2; CCLE 3.5919 5.7396 3.4446 16.8479
STS-0421 GDSC1; GDSC2 4.4173 6.5657 2.4964 2.6743
TE 617.T CTRP2; CCLE 4.4396 6.2473 4.2337 11.4199
BT-12 CTRP2 7.2985 8.5556 5.6167 0.4036
SW982 GDSC1; GDSC2; CTRP2 7.8175 8.9628 5.6745 0.1138
KYM-1 GDSC1; GDSC2; CTRP2 7.8426 9.4715 5.4985 0.4184
HT-1080 GDSC1; GDSC2; CTRP2 7.9464 9.3912 5.5706 0.2364
RKN GDSC1; GDSC2; CTRP2; CCLE 7.9593 9.9004 5.3829 0.6378
BT-16 CTRP2 7.9779 9.3237 5.6069 0.1701
SK-LMS-1 GDSC1; GDSC2; CTRP2 8.2334 9.9625 5.4749 0.3151
SK-UT-1 GDSC1; GDSC2; CTRP2 8.3972 9.9181 5.5532 0.1515
RD GDSC1; GDSC2; CTRP2 8.4075 10.2563 5.4362 0.3282
G-401 GDSC1; GDSC2; CTRP2; CCLE 8.4605 10.5474 5.3494 0.4786
Tm87-16 CTRP2 8.4854 9.8278 5.6153 0.0742
TTC-709 CTRP2 8.6966 10.1603 5.5765 0.0821
Rh18 GDSC1; CTRP2 12.208 24.8442 1.1493 10.3295
Rh41 GDSC1; GDSC2; CTRP2 12.8345 26.5255 0.7569 10.7983
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 50 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 8.5675 17.0826 2.4602 10.5576
JHOS-4 GDSC1; GDSC2; CCLE 2.3537 3.6964 2.1437 9.0443
OAW42 GDSC1; GDSC2; CTRP2 2.63 2.9933 2.63 22.747
OVCAR-5 GDSC1; GDSC2; CTRP2 2.686 3.4809 2.6859 22.3745
COV318 CCLE 2.9415 3.7978 2.5513 2.5809
OVKATE GDSC1; GDSC2 3.023 4.3986 0.5538 0.2434
ES-2 GDSC1; GDSC2 3.0901 4.5525 0.5244 0.2829
A2780 GDSC1; GDSC2; CTRP2; CCLE 3.3156 5.4958 3.1962 18.5896
COV504 CCLE 3.4175 5.5628 2.0477 4.2098
OVMANA CCLE 3.5874 5.6747 2.1149 3.5167
OC 314 GDSC1; GDSC2; CTRP2; CCLE 3.6743 4.6643 3.6696 15.8054
COV362 CTRP2 3.6914 5.6483 3.5727 16.0845
TYK-nu GDSC1; GDSC2; CTRP2; CCLE 3.7005 5.8383 3.5396 16.1735
TOV-21G GDSC1; GDSC2; CCLE 3.8457 8.1867 1.0732 8.2616
Caov-4 GDSC1; GDSC2 3.8696 5.8152 0.3691 0.3412
SNU-119 CTRP2 4.0369 5.5564 3.9649 13.6202
TOV-112D GDSC1; GDSC2; CTRP2; CCLE 4.1532 7.5746 3.4275 15.2939
EFO-27 GDSC1; GDSC2; CTRP2; CCLE 4.2241 5.6599 4.148 12.3879
OC 316 CCLE 4.3708 6.2993 2.3041 1.4353
OVCAR-3 GDSC1; GDSC2; CCLE 4.6248 6.3984 2.3883 0.8461
SNU-840 CTRP2 5.2905 8.3985 4.1923 9.3734
OC 315 CCLE 5.4057 7.1606 2.427 0.3294
OV56 GDSC1; GDSC2; CTRP2 7.3481 8.2278 5.7592 0.1009
SNU-8 CTRP2 7.5498 8.7823 5.6368 0.2469
FU-OV-1 GDSC1; GDSC2; CTRP2; CCLE 7.9386 9.4011 5.564 0.2503
OVSAHO CTRP2; CCLE 7.9586 9.29 5.6116 0.1679
DOV13 GDSC1; GDSC2; CTRP2; CCLE 8.0258 9.7727 5.4611 0.4211
COV644 CTRP2 8.1197 9.7792 5.4971 0.3124
SK-OV-3 GDSC1; GDSC2; CTRP2; CCLE 8.139 9.7094 5.5302 0.2475
OVISE GDSC1; GDSC2; CTRP2 8.1421 9.2234 5.6998 0.0459
ES2 CTRP2 8.1897 9.248 5.7077 0.0371
Caov-3 GDSC2; CTRP2 8.2743 9.7162 5.5786 0.1438
OVK18 GDSC1; GDSC2; CTRP2 8.3512 9.7991 5.5778 0.1305
RMG-I GDSC1; GDSC2; CTRP2 8.3588 10.3884 5.3672 0.4829
JHOS-2 GDSC1; GDSC2; CTRP2; CCLE 8.3898 9.8409 5.5772 0.1244
JHOC-5 CTRP2 8.39 11.5535 4.9118 1.7175
ONCO-DG-1 CTRP2; CCLE 8.3957 9.6014 5.6603 0.05
OVTOKO GDSC1; GDSC2; CTRP2; CCLE 8.4678 10.1685 5.4912 0.2205
EFO-21 GDSC1; GDSC2; CTRP2; CCLE 8.4884 9.8357 5.6137 0.0752
COV434 CTRP2 8.5073 12.1706 4.7086 2.2833
OV-90 GDSC1; GDSC2; CTRP2; CCLE 8.5086 10.2398 5.4812 0.2251
JHOM-1 CTRP2 8.5507 9.9513 5.5964 0.0824
IGROV-1 GDSC1; GDSC2; CTRP2; CCLE 8.5885 10.4539 5.435 0.2757
OVCAR-4 GDSC1; GDSC2; CTRP2; CCLE 8.6975 10.2623 5.5422 0.113
Kuramochi GDSC1; GDSC2; CTRP2; CCLE 8.7161 10.5715 5.4414 0.2329
MCAS CTRP2; CCLE 8.7354 10.4609 5.4874 0.1673
OVCAR-8 GDSC1; GDSC2; CTRP2; CCLE 8.909 10.5279 5.5262 0.0996
OAW28 GDSC1; GDSC2; CTRP2 9.2372 11.053 5.463 0.1144
OV7 CTRP2 9.5013 21.8869 0.7863 14.8614
HEY A8 CTRP2; CCLE 10.479 18.4889 3.014 6.1852
⏷ Show the Full List of 50 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IST-Mes2 CCLE 2.8335 4.7065 2.0044 5.8239
MPP 89 GDSC1; GDSC2; CTRP2; CCLE 3.5312 5.1736 3.4811 16.913
NCI-H2452 GDSC1; GDSC2; CTRP2; CCLE 4.2673 8.0825 3.327 15.3849
NCI-H28 GDSC1; GDSC2; CTRP2; CCLE 6.7879 12.3698 3.4779 9.4012
IST-Mes1 GDSC1; GDSC2; CTRP2; CCLE 7.3584 10.1222 4.9687 2.5261
MSTO-211H GDSC1; GDSC2; CTRP2; CCLE 7.5573 15.4955 2.5127 11.9208
ACC-MESO-1 CTRP2 7.8385 10.0141 5.2803 0.998
NCI-H2052 GDSC1; GDSC2; CTRP2; CCLE 8.8658 10.3108 5.5841 0.0596
JL-1 CTRP2 17.9242 51.9815 -7.9376 22.6297
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PC-3 GDSC1; GDSC2; CCLE 3.9558 6.2304 2.0949 2.8939
NCI-H660 GDSC2 4.532 6.5335 2.5772 2.1482
PaCa-3 CTRP2 4.9791 5.6852 4.9566 7.1735
DU145 GDSC1; GDSC2; CTRP2; CCLE 5.5683 8.5153 4.3928 7.9192
VCaP GDSC1; GDSC2; CTRP2 8.1208 9.6592 5.5412 0.2344
LNCaP clone FGC GDSC1; GDSC2; CTRP2 8.381 18.7856 1.5006 14.2355
22Rv1 GDSC1; GDSC2; CTRP2; CCLE 8.7314 13.2245 4.3691 3.2405
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1; GDSC2; CCLE 4.0561 6.1332 2.2015 2.2363
YD-15 CTRP2 7.8021 9.0766 5.6285 0.1823
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1; GDSC2 3.0485 5.4784 2.0081 8.8314
Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-39 GDSC1; GDSC2 1.9502 4.9179 -0.2348 5.4447
SNU-16 GDSC1; GDSC2; CTRP2; CCLE 2.1781 3.4885 2.1763 25.7638
HGC-27 GDSC1; GDSC2; CTRP2; CCLE 2.3995 3.929 2.3922 24.3071
RF-48 GDSC1; GDSC2 2.4213 5.4241 -0.1697 4.1475
GCIY GDSC1; GDSC2; CCLE 2.5372 3.453 2.3262 4.8602
TGBC11TKB GDSC1; GDSC2 2.7155 4.8828 0.2333 1.6018
SK-GT-2 GDSC1; GDSC2 2.9513 5.389 0.1393 1.7691
AZ-521 CCLE 3.1853 6.0573 1.6229 7.0121
OCUM-1 GDSC1; GDSC2; CCLE 3.4044 5.3982 2.119 3.7533
ECC10 GDSC1; GDSC2; CTRP2 3.8499 6.7291 3.4329 16.1186
MKN1 GDSC1; GDSC2; CTRP2 3.8667 5.3128 3.8203 14.6655
Hs 746.T GDSC1; GDSC2; CTRP2; CCLE 4.0986 6.3869 3.8183 13.9594
MKN28 GDSC1; GDSC2 4.2323 6.3245 0.3241 0.3154
KATO III GDSC1; GDSC2; CTRP2 4.3987 9.568 2.7754 17.2325
BGC-823 CCLE 4.8561 7.5982 2.0013 2.1837
SCH GDSC1; GDSC2 5.0067 6.2634 2.9106 0.2839
RERF-GC-1B GDSC1; GDSC2; CCLE 5.535 7.8779 2.2126 0.7907
KE-39 CTRP2; CCLE 5.6425 9.0108 4.2143 8.5044
TMK-1 GDSC1; GDSC2 6.1132 7.8236 2.7717 0.2062
GSU CTRP2 6.2257 10.9905 3.7208 9.4096
IM95 GDSC1; GDSC2; CTRP2; CCLE 7.311 9.2605 5.3289 1.271
MKN45 GDSC1; GDSC2; CTRP2; CCLE 7.3508 8.5219 5.6525 0.2935
SNU-5 GDSC1; GDSC2; CTRP2 7.5488 8.9333 5.5794 0.3689
NCI-N87 GDSC1; GDSC2; CTRP2; CCLE 7.6603 11.6346 4.4539 4.1331
SNU-620 CTRP2 7.7426 9.1306 5.5854 0.2769
23132/87 GDSC1; GDSC2; CTRP2 7.8622 10.0092 5.2939 0.9415
AGS GDSC1; GDSC2; CTRP2 8.0146 9.7628 5.4601 0.4279
Fu97 GDSC1; GDSC2; CTRP2 8.0206 9.8415 5.4326 0.4866
GSS CTRP2 8.0376 9.6242 5.5214 0.2952
MKN7 GDSC1; GDSC2; CTRP2; CCLE 8.0737 11.8172 4.6225 3.0113
NUGC-4 GDSC1; GDSC2; CTRP2; CCLE 8.1087 9.8051 5.4831 0.3432
ECC12 GDSC2; CTRP2 8.1371 9.329 5.6627 0.0755
HuG1-N CTRP2 8.1468 10.159 5.3647 0.5852
SNU-668 CTRP2 8.1693 9.394 5.6519 0.0812
SNU-719 CTRP2 8.4614 10.332 5.4297 0.3224
SNU-216 CTRP2 8.6844 10.4447 5.4744 0.1942
MKN74 CTRP2; CCLE 8.9464 10.6201 5.508 0.1112
SNU-601 CTRP2 8.97 10.303 5.6214 0.0324
NUGC-3 GDSC1; GDSC2; CTRP2; CCLE 9.0842 19.3929 1.7022 12.4919
SNU-1 GDSC1; GDSC2; CTRP2; CCLE 9.1656 16.747 3.0168 7.6923
LMSU CTRP2 10.5316 17.5922 3.4421 4.6846
SH-10-TC CTRP2; CCLE 11.1224 23.317 1.1843 11.4774
SNU-685 CTRP2 7.9654 9.3931 5.5773 0.2195
SNG-M GDSC1; GDSC2; CTRP2; CCLE 8.1102 14.835 3.2289 8.3147
SNU-1077 CTRP2 8.9687 10.3312 5.6118 0.0368
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
ASH-3 GDSC1; GDSC2 1.9376 3.5816 0.3815 1.8866
HTC-C3 GDSC1; GDSC2 2.2182 5.0982 -0.1447 4.3743
K5 GDSC1; GDSC2 2.4808 4.1409 0.4249 0.9992
SW579 CTRP2; CCLE 2.4861 8.4337 1.3222 27.736
WRO GDSC1; GDSC2 2.9478 4.4999 0.4883 0.4361
IHH-4 GDSC1; GDSC2 3.037 4.4248 0.5498 0.2471
8505C GDSC1; GDSC2; CTRP2; CCLE 3.1025 5.1285 3.0296 19.8468
KMH-2 GDSC1; GDSC2 3.2813 6.4689 1.7144 9.9288
TT2609-C02 GDSC1; GDSC2; CTRP2; CCLE 3.9197 5.6678 3.8166 14.5097
ML-1 [Human leukemia] GDSC1; GDSC2; CTRP2 4.8602 7.3655 4.2499 10.1908
CAL-62 GDSC1; GDSC2; CTRP2 6.552 9.4837 4.7273 4.6302
CGTH-W-1 GDSC1; GDSC2; CTRP2 7.4515 18.1108 1.14 16.9762
FTC-133 GDSC1; GDSC2; CTRP2 7.9971 11.9841 4.5011 3.5451
TT GDSC1; GDSC2; CTRP2 8.3026 10.5804 5.2687 0.7408
FTC-238 CTRP2 8.3054 9.4275 5.6874 0.0404
B-CPAP GDSC1; GDSC2; CTRP2; CCLE 8.3738 16.3676 2.6715 10.057
BHT-101 GDSC1; GDSC2; CTRP2 8.4488 9.9846 5.5488 0.147
8305C GDSC1; GDSC2; CTRP2; CCLE 8.4606 9.8226 5.6085 0.0829
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HO-1-u-1 GDSC1; GDSC2 1.7182 4.514 -0.2004 5.7463
JHU-022 GDSC1; GDSC2 1.8023 3.9121 0.146 3.4707
SAS GDSC1; GDSC2 1.8835 3.6222 0.3316 2.249
BB30-HNC GDSC1; GDSC2 2.4559 3.3795 2.3605 8.8786
SCC-4 GDSC1; GDSC2; CTRP2 2.6607 3.6713 2.6601 22.5447
PCI-30 GDSC1; GDSC2 2.703 5.771 -0.1602 3.6226
BICR 10 GDSC1; GDSC2 2.8673 4.8757 0.309 1.1182
OSC-20 GDSC1; GDSC2 2.8794 4.9876 0.2696 1.2703
LB771-HNC GDSC1; GDSC2 2.9057 6.558 -0.3973 4.5894
NCI-H3118 GDSC1; GDSC2 2.9186 5.4714 0.0883 2.0451
KON GDSC1; GDSC2 2.9228 4.7467 2.2546 7.7381
BICR 78 GDSC1; GDSC2 2.9763 5.8375 -0.038 2.5888
PCI-04B GDSC1; GDSC2 3.0065 4.8145 2.2988 7.1996
HO-1-N-1 GDSC1; GDSC2 3.1004 4.6657 0.4878 0.3653
PCI-15A GDSC1; GDSC2 3.2425 4.8194 2.506 5.2146
SKN-3 GDSC1; GDSC2 3.2963 5.1415 0.3911 0.5302
BB49-HNC GDSC1; GDSC2 3.3412 5.7372 0.1822 1.2092
SAT [Human HNSCC] GDSC1; GDSC2 3.3431 13.2698 -3.3087 18.2961
PCI-38 GDSC1 3.3757 6.7755 -0.2308 3.7491
HSC-4 GDSC1; GDSC2; CTRP2 3.4355 5.5676 3.3119 17.8056
PCI-06A GDSC1; GDSC2 3.4627 5.6787 2.2587 6.1139
KOSC-2 GDSC1; GDSC2 3.4655 6.4856 1.8581 8.546
OSC-19 GDSC1; GDSC2 3.4795 11.1489 -0.4611 21.0458
PE/CA-PJ41 (clone D2) CTRP2 3.5322 4.955 3.5059 16.8251
Hs 840.T CCLE 3.5779 6.8257 1.5448 6.5554
Ca9-22 GDSC1; GDSC2 3.5985 5.9168 0.2246 0.8656
YD-8 CTRP2 3.7087 4.4327 3.7082 15.5624
UPCI-SCC-090 GDSC1; GDSC2 3.7251 5.7715 0.3298 0.4881
SCC-15 GDSC1; GDSC2 3.8801 5.6968 0.4143 0.2509
DOK GDSC1; GDSC2 3.8924 5.7812 0.3894 0.2932
PE/CA-PJ15 GDSC1; GDSC2; CTRP2 4.317 5.8378 4.2113 11.8735
JHU-011 GDSC1; GDSC2 4.607 12.3507 -0.1714 16.7615
HSC-2 GDSC1; GDSC2; CTRP2; CCLE 4.6475 6.3812 4.4162 10.133
PE/CA-PJ49 CTRP2 4.6581 5.3299 4.6516 9.2575
JHU-029 GDSC1; GDSC2 5.0194 8.4894 1.9784 4.4856
FaDu GDSC1; GDSC2; CTRP2; CCLE 5.0401 7.4068 4.4146 9.0726
PE/CA-PJ34 (clone C12) CTRP2 7.1927 10.57 4.6522 3.9708
SNU-1066 CTRP2 7.4373 10.6797 4.7592 3.2312
BICR 18 CTRP2 7.7743 9.4385 5.4818 0.4895
SNU-899 CTRP2 7.7996 9.2725 5.5557 0.3144
CAL-27 GDSC1; GDSC2; CTRP2 7.8589 8.9106 5.7072 0.0712
BICR 22 GDSC1; GDSC2; CTRP2 7.9216 9.2855 5.5992 0.1963
YD-10B CTRP2 8.0092 9.4261 5.5823 0.1994
BICR 56 CTRP2 8.1399 9.4749 5.6137 0.1266
SCC-9 GDSC1; GDSC2; CTRP2 8.1409 10.21 5.3422 0.6429
SCC-25 GDSC1; GDSC2; CTRP2 8.1763 10.0007 5.4376 0.4089
HSC-3 GDSC1; GDSC2; CTRP2 8.2599 15.7033 2.9134 9.31
BHY GDSC1; GDSC2; CTRP2 8.2733 10.2757 5.374 0.5046
SNU-1076 CTRP2 8.3456 9.6432 5.6291 0.0791
SNU-1214 CTRP2 8.3516 9.94 5.5286 0.194
SNU-46 CTRP2 8.3534 10.0016 5.5073 0.225
CAL-33 GDSC1; GDSC2; CTRP2 8.439 9.9409 5.5604 0.1351
BICR 31 GDSC2; CTRP2 8.4792 10.036 5.5419 0.1495
Detroit 562 GDSC1; GDSC2; CTRP2; CCLE 8.5317 11.5099 5.0008 1.337
SNU-1041 CTRP2 8.6394 10.1029 5.576 0.0893
BICR 16 CTRP2 8.6898 10.1702 5.5708 0.0876
BICR 6 CTRP2 13.2986 32.8886 -1.9203 17.0941
⏷ Show the Full List of 57 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-BLC1 CTRP2 2.6739 3.3829 2.6738 22.4551
TCCSUP GDSC1; GDSC2; CTRP2; CCLE 3.1821 4.0641 3.1815 19.071
SW780 GDSC1; GDSC2; CCLE 3.8901 5.8217 2.2439 2.2771
CAL-29 GDSC1; GDSC2; CTRP2 4.0343 5.2999 4.0002 13.5069
BC-3C CTRP2 4.1203 6.0201 3.9511 13.4098
HT-1197 GDSC1; GDSC2; CTRP2; CCLE 4.3756 5.7057 4.3033 11.3657
UM-UC-3 GDSC1; GDSC2; CTRP2; CCLE 5.2925 7.7314 4.5144 8.0465
BFTC-905 GDSC1; GDSC2; CTRP2 5.407 6.3016 5.2648 4.7611
253J-BV CTRP2 7.2374 10.1535 4.8786 3.0192
639V GDSC1; GDSC2; CTRP2; CCLE 7.4773 8.5695 5.6861 0.1804
253J CTRP2 7.8005 9.2537 5.5631 0.2993
KU-19-19 GDSC1; GDSC2; CTRP2 7.8286 8.9054 5.6983 0.0846
JMSU-1 CTRP2; CCLE 7.9199 9.4147 5.5516 0.279
647V GDSC1; GDSC2; CTRP2 7.9762 9.385 5.5844 0.2049
RT-112 GDSC1; GDSC2; CTRP2; CCLE 8.1934 9.6626 5.5676 0.1756
RT-4 GDSC1; GDSC2; CTRP2; CCLE 8.2555 10.1481 5.4149 0.4244
SCaBER CTRP2; CCLE 8.289 9.5984 5.6245 0.0908
UM-UC-1 CTRP2 8.3354 9.9611 5.515 0.2179
SW1710 GDSC1; GDSC2; CTRP2 8.3652 9.9132 5.5431 0.171
VM-CUB-1 CTRP2 8.6493 10.4462 5.4608 0.2209
HT-1376 GDSC1; GDSC2; CTRP2; CCLE 8.7631 16.1312 3.047 8.1036
T24 GDSC1; GDSC2; CTRP2; CCLE 8.8054 15.4852 3.3787 6.8034
KMBC-2 CTRP2; CCLE 8.8082 10.6791 5.4378 0.2167
5637 GDSC1; GDSC2; CTRP2; CCLE 8.9506 10.8026 5.4468 0.1759
J82 GDSC1; GDSC2; CTRP2 9.0209 10.8202 5.4661 0.1421
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HEY GDSC1; GDSC2 1.4035 3.7247 -0.0425 5.5155
SKN GDSC1; GDSC2 1.5946 6.2098 -1.1274 11.6992
MS751 GDSC1; GDSC2 1.9246 3.8457 0.254 2.6156
DSH1 GDSC1; GDSC2 2.2657 5.4717 -0.2895 5.1278
HEC-1 GDSC1; GDSC2 2.4869 6.4799 -0.622 6.6321
SiHa GDSC1; GDSC2 2.5027 3.7193 0.5982 0.3565
SW756 GDSC1; GDSC2 2.66 4.2153 0.4762 0.6502
TC-YIK GDSC1; GDSC2 2.6724 4.7952 0.2483 1.5809
NEC8 GDSC1; GDSC2 2.8818 4.2149 0.566 0.2678
OV17R GDSC1; GDSC2 2.8855 4.7211 2.2321 7.9968
PA-1 GDSC1; GDSC2 2.9328 5.0876 0.2542 1.2837
C-4-I GDSC1; GDSC2 3.0127 4.7192 0.4331 0.5629
ME-180 GDSC1; GDSC2 3.1077 5.2773 0.2588 1.1078
OVCA433 GDSC1; GDSC2 3.1302 4.3129 2.6588 4.6261
LB831-BLC GDSC1; GDSC2 3.1639 4.795 0.4656 0.3932
Ca Ski GDSC1; GDSC2 3.2421 5.5863 0.1972 1.235
PWR-1E GDSC1; GDSC2 3.2837 5.16 0.3791 0.5714
CAL-39 GDSC1; GDSC2 3.3287 5.2424 0.3667 0.5832
NCC-IT GDSC2 3.3641 5.1577 0.412 0.4404
JAR GDSC1; GDSC2 3.3723 4.7886 2.6301 4.0895
DoTc2 4510 GDSC1; GDSC2 3.4925 5.2956 0.4117 0.3858
SKG-IIIa GDSC1; GDSC2 3.5013 5.0027 0.5176 0.1741
OVCA420 GDSC1; GDSC2 3.518 5.0628 0.503 0.1937
JEG-3 GDSC1; GDSC2 3.5384 5.2645 2.5247 4.2985
C-33 A GDSC1; GDSC2 3.6321 5.5292 0.3813 0.4015
UWB1.289 GDSC1; GDSC2 3.7428 6.2415 2.1963 5.7847
NT2-D1 GDSC1; GDSC2 3.7912 5.4669 0.4616 0.1944
PEO1 GDSC1; GDSC2 3.8477 5.9921 0.2975 0.5156
KGN GDSC1; GDSC2 3.869 5.9328 0.327 0.4343
ACC-OV7 GDSC1; GDSC2 3.9279 11.3911 -0.2194 18.7118
JHOS-3 GDSC1; GDSC2 4.1145 5.8678 2.6333 2.4355
OMC-1 [Human cervical carcinoma] GDSC1; GDSC2 4.1271 6.5248 2.3316 4.1309
OVMIU GDSC1; GDSC2 4.3502 6.4018 0.34 0.2556
HT-3 GDSC1; GDSC2 4.3737 6.165 0.4284 0.1295
BPH-1 GDSC1; GDSC2 4.5062 7.5696 -0.0217 1.0873
SiSo GDSC1; GDSC2 4.6081 6.2639 0.4745 0.0627
SW962 GDSC1; GDSC2 5.451 7.1948 2.7452 0.5085
SW954 GDSC1; GDSC2 5.6477 7.4629 2.7249 0.4656
HeLa GDSC1; GDSC2; CTRP2 11.4881 30.2109 -1.858 19.1361
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nilotinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Nilotinib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [18]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Nilotinib caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [19]
Coadministration of a Drug Treating the Disease Different from Nilotinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Nilotinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [20]
Sarecycline DMLZNIQ Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [18]
Metreleptin DM1NOEK Moderate Increased metabolism of Nilotinib caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [18]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Nilotinib and Ivosidenib. Acute myeloid leukaemia [2A60] [21]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Nilotinib and Midostaurin. Acute myeloid leukaemia [2A60] [21]
Arn-509 DMT81LZ Major Increased metabolism of Nilotinib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [18]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Nilotinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [21]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Nilotinib and Levalbuterol. Asthma [CA23] [22]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Nilotinib and Retigabine. Behcet disease [4A62] [21]
Cariprazine DMJYDVK Moderate Decreased metabolism of Nilotinib caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [23]
Erdafitinib DMI782S Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [24]
Pexidartinib DMS2J0Z Major Decreased metabolism of Nilotinib caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [25]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Nilotinib and Eribulin. Breast cancer [2C60-2C6Y] [21]
Talazoparib DM1KS78 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [26]
LY2835219 DM93VBZ Moderate Decreased metabolism of Nilotinib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [27]
Tucatinib DMBESUA Major Decreased metabolism of Nilotinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
Palbociclib DMD7L94 Moderate Decreased metabolism of Nilotinib caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Alpelisib DMEXMYK Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [18]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Nilotinib caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [28]
Bosutinib DMTI8YE Moderate Decreased metabolism of Nilotinib caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Macitentan DMP79A1 Moderate Decreased metabolism of Nilotinib caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [29]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Nilotinib and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [21]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Nilotinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [30]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Nilotinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [22]
Fidaxomicin DMFP6MV Minor Decreased clearance of Nilotinib due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [20]
Intedanib DMSTA36 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [31]
Ulipristal DMBNI20 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Ulipristal. Contraceptive management [QA21] [18]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Nilotinib and Pasireotide. Cushing syndrome [5A70] [21]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Nilotinib and Osilodrostat. Cushing syndrome [5A70] [21]
Lumacaftor DMCLWDJ Major Increased metabolism of Nilotinib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [32]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Nilotinib caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [18]
MK-8228 DMOB58Q Moderate Decreased metabolism of Nilotinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [18]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Nilotinib caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [33]
Desvenlafaxine DMHD4PE Moderate Decreased metabolism of Nilotinib caused by Desvenlafaxine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [18]
OPC-34712 DMHG57U Major Decreased metabolism of Nilotinib caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [34]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Nilotinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [35]
SODIUM CITRATE DMHPD2Y Moderate Decreased absorption of Nilotinib due to altered gastric pH caused by SODIUM CITRATE. Discovery agent [N.A.] [20]
Ospemifene DMC4GEI Moderate Decreased metabolism of Nilotinib caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [36]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Nilotinib and Deutetrabenazine. Dystonic disorder [8A02] [21]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Nilotinib and Ingrezza. Dystonic disorder [8A02] [21]
Cenobamate DM8KLU9 Moderate Increased metabolism of Nilotinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Rufinamide DMWE60C Moderate Increased metabolism of Nilotinib caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Nilotinib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [18]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Nilotinib and Cannabidiol. Epileptic encephalopathy [8A62] [19]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Nilotinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [37]
Tazemetostat DMWP1BH Moderate Increased metabolism of Nilotinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [18]
Mirabegron DMS1GYT Minor Decreased metabolism of Nilotinib caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [38]
Dexlansoprazole DM1DBV5 Moderate Increased risk of hypomagnesemia by the combination of Nilotinib and Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [18]
Ripretinib DM958QB Moderate Decreased metabolism of Nilotinib caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [20]
Avapritinib DMK2GZX Moderate Decreased metabolism of Nilotinib caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [19]
Boceprevir DMBSHMF Major Decreased metabolism of Nilotinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [18]
Telaprevir DMMRV29 Major Decreased metabolism of Nilotinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [20]
Daclatasvir DMSFK9V Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [18]
GS-5885 DMSL3DX Moderate Decreased clearance of Nilotinib due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [39]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Nilotinib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [40]
MK-1439 DM215WE Minor Decreased metabolism of Nilotinib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [41]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Nilotinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [21]
Cobicistat DM6L4H2 Major Decreased metabolism of Nilotinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [20]
Dolutegravir DMCZGRE Minor Decreased metabolism of Nilotinib caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [42]
Etravirine DMGV8QU Moderate Decreased metabolism of Nilotinib caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Nilotinib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [21]
Raltegravir DMYURI6 Minor Decreased metabolism of Nilotinib caused by Raltegravir mediated inhibition of UGT. Human immunodeficiency virus disease [1C60-1C62] [44]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Nilotinib and Mipomersen. Hyper-lipoproteinaemia [5C80] [45]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Nilotinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [46]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Nilotinib and BMS-201038. Hyper-lipoproteinaemia [5C80] [47]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Nilotinib due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [19]
Aliskiren DM1BV7W Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [21]
Levamlodipine DM92S6N Moderate Decreased metabolism of Nilotinib caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [18]
Tolvaptan DMIWFRL Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [48]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Nilotinib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [18]
Suvorexant DM0E6S3 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Suvorexant. Insomnia [7A00-7A0Z] [18]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Nilotinib caused by ITI-007 mediated inhibition of UGT. Insomnia [7A00-7A0Z] [49]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Nilotinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [50]
Naloxegol DML0B41 Minor Decreased metabolism of Nilotinib caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [51]
Pemigatinib DM819JF Moderate Decreased metabolism of Nilotinib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [19]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Nilotinib and Denosumab. Low bone mass disorder [FB83] [52]
Brigatinib DM7W94S Moderate Decreased metabolism of Nilotinib caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [20]
PF-06463922 DMKM7EW Moderate Increased metabolism of Nilotinib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [18]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Nilotinib and Osimertinib. Lung cancer [2C25] [21]
Capmatinib DMYCXKL Moderate Decreased metabolism of Nilotinib caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [18]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Nilotinib and Lumefantrine. Malaria [1F40-1F45] [20]
Artesunate DMR27C8 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Artesunate. Malaria [1F40-1F45] [18]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Nilotinib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [21]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Nilotinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [53]
Idelalisib DM602WT Major Decreased metabolism of Nilotinib caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [20]
GDC-0199 DMH0QKA Major Decreased metabolism of Nilotinib caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [20]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Nilotinib caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [54]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Nilotinib caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [55]
Ponatinib DMYGJQO Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [18]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Nilotinib and Vemurafenib. Melanoma [2C30] [21]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Nilotinib and LGX818. Melanoma [2C30] [21]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Nilotinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [18]
Lasmiditan DMXLVDT Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [56]
Flibanserin DM70DTN Moderate Decreased metabolism of Nilotinib caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [57]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Nilotinib and Tecfidera. Multiple sclerosis [8A40] [58]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Nilotinib and Siponimod. Multiple sclerosis [8A40] [20]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Nilotinib and Fingolimod. Multiple sclerosis [8A40] [59]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Nilotinib and Ocrelizumab. Multiple sclerosis [8A40] [60]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Nilotinib and Ozanimod. Multiple sclerosis [8A40] [21]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Nilotinib and Romidepsin. Mycosis fungoides [2B01] [21]
Rolapitant DM8XP26 Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [20]
S-297995 DM26IH8 Moderate Decreased metabolism of Nilotinib caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [19]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Nilotinib and Rucaparib. Ovarian cancer [2C73] [21]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Nilotinib and Triclabendazole. Parasitic worm infestation [1F90] [21]
Istradefylline DM20VSK Moderate Decreased metabolism of Nilotinib caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [18]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Nilotinib and Pimavanserin. Parkinsonism [8A00] [21]
Abametapir DM2RX0I Moderate Decreased metabolism of Nilotinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [61]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Nilotinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [62]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Nilotinib and Lefamulin. Pneumonia [CA40] [63]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Nilotinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [20]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Nilotinib and Degarelix. Prostate cancer [2C82] [21]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Nilotinib and ABIRATERONE. Prostate cancer [2C82] [21]
Enzalutamide DMGL19D Major Increased metabolism of Nilotinib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [18]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Nilotinib and Relugolix. Prostate cancer [2C82] [64]
Darolutamide DMV7YFT Minor Decreased metabolism of Nilotinib caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [65]
Silodosin DMJSBT6 Moderate Decreased metabolism of Nilotinib caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [66]
Selexipag DMAHSU0 Moderate Decreased metabolism of Nilotinib caused by Selexipag mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [67]
Ambrisentan DMD1QXW Moderate Decreased metabolism of Nilotinib caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [18]
Riociguat DMXBLMP Moderate Decreased metabolism of Nilotinib caused by Riociguat mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [20]
Axitinib DMGVH6N Moderate Decreased metabolism of Nilotinib caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [19]
Temsirolimus DMS104F Moderate Decreased metabolism of Nilotinib caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [18]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Nilotinib and Canakinumab. Rheumatoid arthritis [FA20] [68]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Nilotinib and Rilonacept. Rheumatoid arthritis [FA20] [68]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Nilotinib and Golimumab. Rheumatoid arthritis [FA20] [69]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Nilotinib and Iloperidone. Schizophrenia [6A20] [21]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Nilotinib and Amisulpride. Schizophrenia [6A20] [21]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Nilotinib and Asenapine. Schizophrenia [6A20] [21]
LDE225 DMM9F25 Moderate Decreased metabolism of Nilotinib caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [70]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Nilotinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [19]
Larotrectinib DM26CQR Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [20]
PDX-101 DM6OC53 Moderate Decreased metabolism of Nilotinib caused by PDX-101 mediated inhibition of UGT. Solid tumour/cancer [2A00-2F9Z] [71]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Nilotinib caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [19]
Armodafinil DMGB035 Minor Decreased metabolism of Nilotinib caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [20]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Nilotinib and LEE011. Solid tumour/cancer [2A00-2F9Z] [21]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Nilotinib and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [21]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Nilotinib and Pitolisant. Somnolence [MG42] [21]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Nilotinib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [21]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Nilotinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [72]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [18]
Apixaban DM89JLN Moderate Decreased metabolism of Nilotinib caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [19]
Brilinta DMBR01X Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Brilinta. Thrombosis [DB61-GB90] [18]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Nilotinib and Lenvatinib. Thyroid cancer [2D10] [21]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Nilotinib and Cabozantinib. Thyroid cancer [2D10] [21]
Elagolix DMB2C0E Moderate Increased metabolism of Nilotinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [18]
Betrixaban DM2C4RF Moderate Decreased clearance of Nilotinib due to the transporter inhibition by Betrixaban. Venous thromboembolism [BD72] [18]
⏷ Show the Full List of 145 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferric oxide black E00522 16211978 Colorant
Gelatin E00630 Not Available Other agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Colcothar yellow E00436 518696 Colorant
Haematite red E00236 14833 Colorant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
⏷ Show the Full List of 13 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nilotinib Hydrochloride Monohydrate eq 50mg base capsule eq 50mg base Capsule Oral
Nilotinib Hydrochloride Monohydrate eq 150mg base capsule eq 150mg base Capsule Oral
Nilotinib Hydrochloride Monohydrate eq 200mg base capsule eq 200mg base Capsule Oral
Nilotinib 150 mg capsule 150 mg Oral Capsule Oral
Nilotinib 200 mg capsule 200 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5697).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
6 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64.
7 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
8 KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665)
9 Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87.
10 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
11 Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
12 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
13 Nilotinib reduced the viability of human ovarian cancer cells via mitochondria-dependent apoptosis, independent of JNK activation. Toxicol In Vitro. 2016 Mar;31:1-11. doi: 10.1016/j.tiv.2015.11.002. Epub 2015 Nov 6.
14 Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels. Chem Biol Interact. 2017 Aug 1;273:171-179. doi: 10.1016/j.cbi.2017.06.012. Epub 2017 Jun 13.
15 AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.
16 Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells. Chem Biol Interact. 2014 Aug 5;219:203-10. doi: 10.1016/j.cbi.2014.06.009. Epub 2014 Jun 19.
17 p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib. Diseases. 2018 Jan 25;6(1):13. doi: 10.3390/diseases6010013.
18 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Cerner Multum, Inc. "Australian Product Information.".
21 Canadian Pharmacists Association.
22 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
23 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
24 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
25 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
26 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
28 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
29 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
30 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
31 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
32 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
33 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
34 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
35 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
36 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
37 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
38 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
39 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
40 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
41 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
42 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
43 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
44 Product Information. Isentress (raltegravir). Merck & Company Inc, West Point, PA.
45 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
46 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
47 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
48 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
49 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
50 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
51 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
52 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
53 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
54 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
55 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
56 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
57 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
58 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
59 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
60 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
61 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
62 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
63 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
64 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
65 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
66 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
67 Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
68 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
69 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
70 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
71 Product Information. Beleodaq (belinostat). Spectrum Pharmaceuticals Inc, Irvine, CA.
72 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.